APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 4
April 2012



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

32nd EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

32nd EDITION

Cumulative Supplement 4

April 2012

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

32nd EDITION

CUMULATIVE SUPPLEMENT 4
April 2012

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use

in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2011	MAR 2012	JUN 2012	SEPT 2012	DEC 2012
DRUG PRODUCTS LISTED	14480	14711			
SINGLE SOURCE	2451 (16.9%)	2446 (16.6%)			
MULTISOURCE	11953 (82.5%)	12187 (82.8%)			
THERAPEUTICALLY EQUIVALENT	11792 (81.4%)	12037 (81.8%)			
NOT THERAPEUTICALLY EQUIVALENT	161 (1.1%)	150 (1.0%)			
EXCEPTIONS[1]	76 (0.5%)	78 (0.5%)			
NEW MOLECULAR ENTITIES APPROVED	6	8			
NUMBER OF APPLICANTS	810	826			

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACARBOSE

TABLET; ORAL
ACARBOSE

AB		EMCURE PHARMS LTD	25MG	A202271	001	Feb 07, 2012	Jan	NEWA
AB			50MG	A202271	002	Feb 07, 2012	Jan	NEWA
AB			100MG	A202271	003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+	PHARM ASSOC	120MG/5ML;12MG/5ML	A087508	001		Jan	CRLD

SUSPENSION; ORAL
CAPITAL AND CODEINE

	+	VALEANT	120MG/5ML;12MG/5ML	A086024	001		Jan	CTEC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343	001	Jan 25, 2012	Jan	NEWA

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		AUROLIFE PHARMA LLC	325MG;5MG	A201013	001	Apr 11, 2012	Mar	NEWA
AA			325MG;7.5MG	A201013	002	Apr 11, 2012	Mar	NEWA
AA			325MG;10MG	A201013	003	Apr 11, 2012	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

AA		ACTAVIS TOTOWA	325MG;7.5MG	A040800	001	Apr 03, 2012	Mar	NEWA
AA			325MG;10MG	A040800	002	Apr 03, 2012	Mar	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB		ALVOGEN INC	325MG;37.5MG	A202076	001	Mar 30, 2012	Mar	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

>A>	AP		SAGENT STRIDES	EQ 500MG BASE/VIAL	A200880	001	May 09, 2012	Apr	NEWA
>D>	AP		X GEN PHARMS	EQ 500MG BASE/VIAL	A040784	001	Dec 10, 2008	Apr	CRLD
>A>	AP	+		EQ 500MG BASE/VIAL	A040784	001	Dec 10, 2008	Apr	CRLD
>D>			DIAMOX						
>D>	AP	+	DURAMED PHARMS BARR	EQ 500MG BASE/VIAL	N009388	001	Dec 05, 1990	Apr	DISC
>A>			@ TEVA WOMENS	EQ 500MG BASE/VIAL	N009388	001	Dec 05, 1990	Apr	DISC

ADAPALENE

CREAM; TOPICAL
ADAPALENE

AB		FOUGERA PHARMS	0.1%	A090824	001	Jun 30, 2010	Jan	CAHN

LOTION; TOPICAL
DIFFERIN

>A>	+	GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010	Apr	CAHN

LOTION; TOPICAL
DIFFERIN
>D> + GALDERMA R AND D 0.1% N022502 001 Mar 17, 2010 Apr CAHN

ADENOSINE

INJECTABLE; INJECTION
ADENOSINE
@ TEVA PARENTERAL 3MG/ML A078676 001 Jul 31, 2008 Mar DISC
@ 3MG/ML A076564 001 Jun 16, 2004 Jan DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
>D> AN SANDOZ EQ 0.083% BASE;0.017% A076867 001 Dec 21, 2006 Apr DISC
>A> @ SANDOZ INC EQ 0.083% BASE;0.017% A076867 001 Dec 21, 2006 Apr DISC

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL
ALCLOMETASONE DIPROPIONATE
AB FOUGERA PHARMS 0.05% A076973 001 Jul 12, 2005 Jan CAHN

OINTMENT; TOPICAL
ALCLOMETASONE DIPROPIONATE
AB FOUGERA PHARMS 0.05% A076884 001 Jul 18, 2005 Jan CAHN

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL
BINOSTO
+ MISSION PHARMA EQ 70MG BASE N202344 001 Mar 12, 2012 Mar NEWA

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALFUZOSIN HYDROCHLORIDE
AB INVAGEN PHARMS 10MG A090284 001 Jan 17, 2012 Jan NEWA

ALGLUCERASE

INJECTABLE; INJECTION
CEREDASE
@ GENZYME 80 UNITS/ML N020057 003 Apr 05, 1991 Mar DISC

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM
@ SANDOZ INC 0.5MG A077777 001 Jun 30, 2006 Mar DISC
@ 1MG A077777 002 Jun 30, 2006 Mar DISC
@ 2MG A077777 003 Jun 30, 2006 Mar DISC
@ 3MG A077777 004 Jun 30, 2006 Mar DISC

TABLET, ORALLY DISINTEGRATING; ORAL
NIRAVAM
AB UCB INC 0.25MG N021726 001 Jan 19, 2005 Jan CAHN
AB 0.5MG N021726 002 Jan 19, 2005 Jan CAHN
AB + 1MG N021726 003 Jan 19, 2005 Jan CAHN
AB 2MG N021726 004 Jan 19, 2005 Jan CAHN

ALVIMOPAN

CAPSULE; ORAL
ENTEREG

	+	CUBIST PHARMS	12MG	N021775	001	May 20, 2008	Feb	CAHN

AMCINONIDE

CREAM; TOPICAL
AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076065	001	May 15, 2003	Jan	CAHN

LOTION; TOPICAL
AMCINONIDE

	+	FOUGERA PHARMS	0.1%	A076329	001	Nov 06, 2002	Jan	CAHN

OINTMENT; TOPICAL
AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076096	001	Nov 19, 2002	Jan	CAHN

AMINO ACIDS

INJECTABLE; INJECTION
AMINO ACIDS

		B BRAUN	15%(150GM/1000ML)	A091112	001	Apr 13, 2012	Mar	NEWA
			15%(300GM/2000ML)	A091112	002	Apr 13, 2012	Mar	NEWA
		NOVAMINE 15%						
		@ HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986	Mar	CPOT

AMINOCAPROIC ACID

INJECTABLE; INJECTION
AMICAR

		@ CLOVER PHARMS	250MG/ML	N015229	002		Mar	CAHN

SYRUP; ORAL
AMICAR

AA	+	CLOVER PHARMS	1.25GM/5ML	N015230	002		Mar	CAHN

TABLET; ORAL
AMICAR

AB		CLOVER PHARMS	500MG	N015197	001		Mar	CAHN
	+		1GM	N015197	002	Jun 24, 2004	Mar	CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HYDROCHLORIDE

		@ TEVA PARENTERAL	50MG/ML	A076163	001	Sep 05, 2003	Jan	DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HYDROCHLORIDE

>A>	AB	CARACO	10MG	A040816	002	Jun 27, 2008	Apr	NEWA
>A>	AB		50MG	A040816	003	Jun 27, 2008	Apr	NEWA
>A>	AB		75MG	A040816	004	Jun 27, 2008	Apr	NEWA
>A>	AB		100MG	A040816	005	Jun 27, 2008	Apr	NEWA
>A>	AB		150MG	A040816	006	Jun 27, 2008	Apr	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

		MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Feb	CTEC
	+		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Feb	CRLD

TABLET; ORAL
LIMBITROL
@ VALEANT PHARM INTL EQ 12.5MG BASE;5MG N016949 001 Feb DISC
LIMBITROL DS
@ VALEANT PHARM INTL EQ 25MG BASE;10MG N016949 002 Feb DISC

AMLODIPINE BESYLATE

TABLET; ORAL
AMLODIPINE BESYLATE
AB MACLEODS PHARMS LTD EQ 5MG BASE A201380 001 Apr 13, 2012 Mar NEWA
AB EQ 10MG BASE A201380 002 Apr 13, 2012 Mar NEWA

AMOXICILLIN

TABLET, FOR SUSPENSION; ORAL
>D> DISPERMOX
>D> + RANBAXY 600MG A065159 001 Dec 04, 2003 Apr DISC
>A> @ RANBAXY LABS LTD 600MG A065159 001 Dec 04, 2003 Apr DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM
AB AUROBINDO PHARMA LTD 250MG;EQ 125MG BASE A091569 001 Jan 20, 2012 Jan NEWA
AB 500MG;EQ 125MG BASE A091569 002 Jan 20, 2012 Jan NEWA
AB 875MG;EQ 125MG BASE A091568 001 Jan 20, 2012 Jan NEWA

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL
AGRYLIN
AB SHIRE LLC EQ 0.5MG BASE N020333 001 Mar 14, 1997 Jan CAHN
ANAGRELIDE HYDROCHLORIDE
@ SANDOZ INC EQ 0.5MG BASE A076683 001 Apr 18, 2005 Mar DISC
@ EQ 1MG BASE A076683 002 Apr 18, 2005 Mar DISC

ANASTROZOLE

TABLET; ORAL
ANASTROZOLE
>A> AB APOTEX INC 1MG A200654 001 May 11, 2012 Apr NEWA

ARGATROBAN

INJECTABLE; INJECTION
ACOVA
AP + PFIZER 250MG/2.5ML (100MG/ML) N020883 001 Jun 30, 2000 Jan CTNA
ARGATROBAN
AP HIKMA PHARM CO LTD 250MG/2.5ML (100MG/ML) N203049 001 Jan 05, 2012 Jan NEWA

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE
AA NOVEL LABS INC 4.7GM;100GM;1.015GM;5.9MG;2.691GM;7.5GM A090145 001 Jan 25, 2012 Jan NEWA
MOVIPREP
AA + SALIX PHARMS 4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM N021881 001 Aug 02, 2006 Jan CFTG

ASPIRIN; CARISOPRODOL

TABLET; ORAL
CARISOPRODOL AND ASPIRIN

AB		PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901	001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091489	001	Feb 17, 2012	Feb	NEWA

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	+	BEDFORD	10MG/ML	A074900	001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091488	001	Feb 17, 2012	Feb	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D>	AA	ROXANE	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Apr	CRLD
>A>	AA	+	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Apr	CRLD
>D>		LOMOTIL						
>D>	AA	+ GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699	001		Apr	DISC
>A>		@	0.025MG/5ML;2.5MG/5ML	N012699	001		Apr	DISC

>A> AVANAFIL

>A> TABLET; ORAL
>A> STENDRA

>A>		VIVUS	50MG	N202276	001	Apr 27, 2012	Apr	NEWA
>A>			100MG	N202276	002	Apr 27, 2012	Apr	NEWA
>A>	+		200MG	N202276	003	Apr 27, 2012	Apr	NEWA

AXITINIB

TABLET; ORAL
INLYTA

		PFIZER	1MG	N202324	001	Jan 27, 2012	Jan	NEWA
	+		5MG	N202324	002	Jan 27, 2012	Jan	NEWA

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL
EDARBI

>D>		TAKEDA PHARMS	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Apr	CAHN
>D>	+		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Apr	CAHN
>A>		TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Apr	CAHN
>A>	+		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Apr	CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL
EDARBYCLOR

>D>		TAKEDA PHARMS	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Apr	CAHN
>D>	+		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Apr	CAHN
>A>		TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Apr	CAHN

			TABLET; ORAL							
			EDARBYCLOR							
>A>		+	TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Apr	CAHN

BACLOFEN

		TABLET; ORAL							
		BACLOFEN							
AB			PROSAM LABS	10MG	A077089	001	Oct 31, 2007	Feb	CAHN
AB				20MG	A077088	001	Oct 31, 2007	Feb	CAHN
		TABLET, ORALLY DISINTEGRATING; ORAL							
		KEMSTRO							
		@	UCB INC	10MG	N021589	001	Oct 30, 2003	Jan	CAHN
		@		20MG	N021589	002	Oct 30, 2003	Jan	CAHN

BALSALAZIDE DISODIUM

		TABLET; ORAL							
		GIAZO							
	+		SALIX PHARMS	1.1GM	N022205	001	Feb 03, 2012	Feb	NEWA

BECLOMETHASONE DIPROPIONATE

		AEROSOL, METERED; NASAL							
		QNASL							
	+		TEVA BRANDED PHARM	0.08MG/ACTIVATION	N202813	001	Mar 23, 2012	Mar	NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

		GEL; TOPICAL							
		BENZACLIN							
>D>	BT	+	SANOFI AVENTIS US	5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Apr	CAHN
>D>	AB			5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Apr	CAHN
>A>	AB		VALEANT INTL	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Apr	CAHN
>A>	BT	+		5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Apr	CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

		GEL; TOPICAL							
		BENZAMYCIN							
AB	+		VALEANT INTL	5%;3%	N050557	001	Oct 26, 1984	Jan	CAHN

BENZPHETAMINE HYDROCHLORIDE

		TABLET; ORAL							
		BENZPHETAMINE HYDROCHLORIDE							
AA			EMCURE PHARMS LTD	50MG	A202061	001	Jan 27, 2012	Jan	NEWA

BENZTROPINE MESYLATE

		INJECTABLE; INJECTION							
		COGENTIN							
AP	+		OAK PHARMS AKORN	1MG/ML	N012015	001		Feb	CAHN
		TABLET; ORAL							
		BENZTROPINE MESYLATE							
		@	LANNETT HOLDINGS INC	0.5MG	A088877	001	Apr 11, 1985	Jan	DISC
		@		1MG	A088894	001	Apr 11, 1985	Jan	DISC
		@		2MG	A088895	001	Apr 11, 1985	Jan	DISC
AA			PROSAM LABS	0.5MG	A040699	001	Feb 14, 2008	Feb	CMFD
AA				1MG	A040705	001	Feb 14, 2008	Feb	CMFD
AA				2MG	A040706	001	Feb 14, 2008	Feb	CMFD
AA	+		USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Jan	CRLD
AA	+			1MG	A040103	002	Dec 12, 1996	Jan	CRLD

TABLET; ORAL
BENZTROPINE MESYLATE

AA	+	USL PHARMA	2MG	A040103	003	Dec 12, 1996	Jan	CRLD

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137	001	Jun 26, 1984	Jan	CAHN

CREAM, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215	001	Dec 09, 2003	Jan	CAHN

GEL, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276	001	May 13, 2003	Jan	CAHN

LOTION, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111	001	May 21, 2007	Jan	CAHN

OINTMENT, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373	001	Jun 22, 1999	Jan	CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502	001	Jun 05, 2001	Jan	CAHN

LOTION; TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516	001	Jun 16, 2005	Jan	CAHN

LOTRISONE

AB	+	SCHERING CORP	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL
LUXIQ

	+	STIEFEL	EQ 0.12% BASE	N020934	001	Feb 28, 1999	Jan	CAHN

BISOPROLOL FUMARATE

TABLET; ORAL
ZEBETA

AB		TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Jan	CAHN
AB	+		10MG	N019982	001	Jul 31, 1992	Jan	CAHN

BOCEPREVIR

CAPSULE; ORAL
VICTRELIS

	+	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Mar	CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
VELCADE

	+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003	Jan	CDFR

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION
SYMBICORT

	+	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Jan	CDFR

		AEROSOL, METERED; INHALATION						
		SYMBICORT						
	+	ASTRAZENECA	0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Jan	CDFR
>A>		BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE						
>A>		FILM; SUBLINGUAL						
>A>		SUBOXONE						
>A>		RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	Apr	CAIN
>A>	+		EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Apr	CAIN
		TABLET; SUBLINGUAL						
		SUBOXONE						
>D>		RECKITT BENCKISER	2MG;0.5MG	N020733	001	Oct 08, 2002	Apr	CPOT
>A>			EQ 2MG BASE;EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Apr	CPOT
>D>	+		8MG;2MG	N020733	002	Oct 08, 2002	Apr	CPOT
>A>	+		EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002	Apr	CPOT
>D>		BUPRENORPHINE; NALOXONE						
>D>		FILM; SUBLINGUAL						
>D>		SUBOXONE						
>D>		RECKITT BENCKISER	2MG;0.5MG	N022410	001	Aug 30, 2010	Apr	CAIN
>D>	+		8MG;2MG	N022410	002	Aug 30, 2010	Apr	CAIN
		BUPROPION HYDROCHLORIDE						
		TABLET, EXTENDED RELEASE; ORAL						
		FORFIVO XL						
	+	EDGEMONT PHARMS LLC	450MG	N022497	001	Nov 10, 2011	Mar	CAHN
		BUSPIRONE HYDROCHLORIDE						
		TABLET; ORAL						
		BUSPIRONE HYDROCHLORIDE						
	@	APOTEX	5MG	A075521	001	Apr 05, 2002	Mar	DISC
	@		10MG	A075521	002	Apr 05, 2002	Mar	DISC
	@		15MG	A075521	003	Apr 05, 2002	Mar	DISC
	@	EGIS	5MG	A075119	001	Mar 14, 2002	Mar	DISC
	@		10MG	A075119	002	Mar 14, 2002	Mar	DISC
	@		15MG	A075119	003	Jan 23, 2003	Mar	DISC
	@	PROSAM LABS	5MG	A075388	001	May 09, 2002	Mar	DISC
AB			5MG	A075388	001	May 09, 2002	Feb	CMFD
	@		10MG	A075388	002	May 09, 2002	Mar	DISC
AB			10MG	A075388	002	May 09, 2002	Feb	CMFD
	@		15MG	A075388	003	May 09, 2002	Mar	DISC
AB			15MG	A075388	003	May 09, 2002	Feb	CMFD
AB			30MG	A078302	001	Dec 17, 2007	Feb	CMFD
		BUTOCONAZOLE NITRATE						
		CREAM; VAGINAL						
>A>		BUTOCONAZOLE NITRATE						
>A>		@ PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Apr	NEWA
		CAFFEINE CITRATE						
		SOLUTION; INTRAVENOUS						
		CAFCIT						
AP	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Jan	CAHN

SOLUTION; ORAL
CAFCIT

AA	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jan	CAHN

CALCIPOTRIENE

SOLUTION; TOPICAL
CALCIPOTRIENE

AT		FOUGERA PHARMS	0.005%	A078305	001	May 06, 2008	Jan	CAHN

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

>A>		CARBIDOPA, LEVODOPA AND ENTACAPONE						
>A>	AB	SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085	001	May 10, 2012	Apr	NEWA
>A>	AB		37.5MG;200MG;150MG	A079085	002	May 10, 2012	Apr	NEWA
		STALEVO 100						
>D>		ORION	25MG;200MG;100MG	N021485	002	Jun 11, 2003	Apr	CFTG
>A>	AB	ORION PHARMA	25MG;200MG;100MG	N021485	002	Jun 11, 2003	Apr	CFTG
		STALEVO 150						
>D>		ORION	37.5MG;200MG;150MG	N021485	003	Jun 11, 2003	Apr	CFTG
>A>	AB	ORION PHARMA	37.5MG;200MG;150MG	N021485	003	Jun 11, 2003	Apr	CFTG

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL
PARCOPA

AB		UCB INC	10MG;100MG	A076699	001	Aug 27, 2004	Jan	CAHN
AB			25MG;100MG	A076699	002	Aug 27, 2004	Jan	CAHN
AB	+		25MG;250MG	A076699	003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

INJECTABLE; INJECTION
CARBOPLATIN

AP		CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006	Mar	CAHN
AP			150MG/VIAL	A077383	002	Jan 27, 2006	Mar	CAHN
AP			450MG/VIAL	A077383	003	Jan 27, 2006	Mar	CAHN
		PARAPLATIN						
	@	CORDEN PHARMA	50MG/VIAL	N019880	001	Mar 03, 1989	Feb	CAHN
	@		150MG/VIAL	N019880	002	Mar 03, 1989	Feb	CAHN
	@		450MG/VIAL	N019880	003	Mar 03, 1989	Feb	CAHN

INJECTABLE; IV (INFUSION)
CARBOPLATIN

AP		ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Jan	NEWA
AP			150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Jan	NEWA
AP			450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Jan	NEWA
AP			600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Jan	NEWA
AP		CIPLA LTD	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	Mar	CAHN
AP			150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	Mar	CAHN
AP			450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	Mar	CAHN
AP			600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	Mar	CAHN

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA		PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Feb	CAHN

CEFACLOR

CAPSULE; ORAL
CEFACLOR

>D>	AB		RANBAXY	EQ 250MG BASE	A064156	001	Aug 28, 1997	Apr	DISC
>A>			@	EQ 250MG BASE	A064156	001	Aug 28, 1997	Apr	DISC
>D>	AB			EQ 500MG BASE	A064156	002	Aug 28, 1997	Apr	DISC
>A>			@	EQ 500MG BASE	A064156	002	Aug 28, 1997	Apr	DISC

FOR SUSPENSION; ORAL
CEFACLOR

>D>	AB	+	RANBAXY	EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997	Apr	DISC
>A>			@	EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997	Apr	DISC
	AB	+		EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997	Feb	CTEC
>D>	AB	+		EQ 187MG BASE/5ML	A064165	001	Oct 02, 1997	Apr	DISC
>A>			@	EQ 187MG BASE/5ML	A064165	001	Oct 02, 1997	Apr	DISC
	AB	+		EQ 187MG BASE/5ML	A064165	001	Oct 02, 1997	Feb	CTEC
>D>	AB	+		EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997	Apr	DISC
>A>			@	EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997	Apr	DISC
	AB	+		EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997	Feb	CTEC
>D>	AB	+		EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997	Apr	DISC
>A>			@	EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997	Apr	DISC
	AB	+		EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997	Feb	CTEC
	AB		YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012	Feb	NEWA
	AB			EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012	Feb	NEWA
	AB			EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012	Feb	NEWA
	AB			EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Feb	NEWA

TABLET, CHEWABLE; ORAL
RANICLOR

>D>			RANBAXY	EQ 125MG BASE	A065092	001	Dec 22, 2003	Apr	DISC
>D>				EQ 187MG BASE	A065092	002	Dec 22, 2003	Apr	DISC
>D>				EQ 250MG BASE	A065092	003	Dec 22, 2003	Apr	DISC
>D>		+		EQ 375MG BASE	A065092	004	Dec 22, 2003	Apr	DISC
>A>			@ RANBAXY LABS LTD	EQ 125MG BASE	A065092	001	Dec 22, 2003	Apr	DISC
>A>			@	EQ 187MG BASE	A065092	002	Dec 22, 2003	Apr	DISC
>A>			@	EQ 250MG BASE	A065092	003	Dec 22, 2003	Apr	DISC
>A>		+	@	EQ 375MG BASE	A065092	004	Dec 22, 2003	Apr	DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

>D>	AB		RANBAXY	EQ 500MG BASE	A065015	001	Jun 22, 1999	Apr	DISC
>A>			@ RANBAXY LABS LTD	EQ 500MG BASE	A065015	001	Jun 22, 1999	Apr	DISC

TABLET; ORAL
CEFADROXIL

>D>	AB		RANBAXY	EQ 1GM BASE	A065018	001	Apr 23, 1999	Apr	DISC
>A>			@	EQ 1GM BASE	A065018	001	Apr 23, 1999	Apr	DISC

CEFDITOREN PIVOXIL

TABLET; ORAL
SPECTRACEF

			VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001	Mar	CAHN
		+		400MG	N021222	002	Jul 21, 2008	Mar	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

			CLAFORAN						
	AP	+	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987	Mar	CRLD
	AP	+		EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987	Mar	CRLD

CEFPROZIL

FOR SUSPENSION; ORAL

			CEFPROZIL						
	AB		APOTEX INC	125MG/5ML	A065351	001	Feb 29, 2012	Feb	NEWA
	AB			250MG/5ML	A065351	002	Feb 29, 2012	Feb	NEWA
>D>	AB		RANBAXY	125MG/5ML	A065202	001	Jun 30, 2006	Apr	DISC
>D>	AB			250MG/5ML	A065202	002	Jun 30, 2006	Apr	DISC
>A>		@	RANBAXY LABS LTD	125MG/5ML	A065202	001	Jun 30, 2006	Apr	DISC
>A>		@		250MG/5ML	A065202	002	Jun 30, 2006	Apr	DISC

TABLET; ORAL

			CEFPROZIL						
>D>	AB		RANBAXY	250MG	A065198	001	Dec 13, 2006	Apr	DISC
>D>	AB			500MG	A065198	002	Dec 13, 2006	Apr	DISC
>A>		@	RANBAXY LABS LTD	250MG	A065198	001	Dec 13, 2006	Apr	DISC
>A>		@		500MG	A065198	002	Dec 13, 2006	Apr	DISC
			CEFZIL						
		@	CORDEN PHARMA	250MG	N050664	001	Dec 23, 1991	Feb	CAHN
		@		500MG	N050664	002	Dec 23, 1991	Feb	CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

			FORTAZ						
>A>	AP	+	COVIS PHARMA	500MG/VIAL	N050578	001	Jul 19, 1985	Apr	CAHN
>A>	AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Apr	CAHN
>A>	AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Apr	CAHN
>A>	AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Apr	CAHN
>D>	AP	+	GLAXOSMITHKLINE	500MG/VIAL	N050578	001	Jul 19, 1985	Apr	CAHN
>D>	AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Apr	CAHN
>D>	AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Apr	CAHN
>D>	AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

			FORTAZ IN PLASTIC CONTAINER						
>A>		@	COVIS PHARMA	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Apr	CAHN
>A>		+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Apr	CAHN
>A>		+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Apr	CAHN
>D>		@	GLAXOSMITHKLINE	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Apr	CAHN
>D>		+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Apr	CAHN
>D>		+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Apr	CAHN

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

			CEFTRIAXONE						
	AP	+	SANDOZ INC	EQ 1GM BASE/VIAL	A065204	001	May 03, 2005	Mar	CRLD
	AP	+		EQ 2GM BASE/VIAL	A065204	002	May 03, 2005	Mar	CRLD

CEFUROXIME AXETIL

TABLET; ORAL
CEFUROXIME AXETIL

>D>	AB		RANBAXY	EQ 125MG BASE	A065043	003	Feb 15, 2002	Apr	DISC
>D>	AB			EQ 250MG BASE	A065043	002	Feb 15, 2002	Apr	DISC
>D>	AB			EQ 500MG BASE	A065043	001	Feb 15, 2002	Apr	DISC
>A>			@ RANBAXY LABS LTD	EQ 125MG BASE	A065043	003	Feb 15, 2002	Apr	DISC
>A>			@	EQ 250MG BASE	A065043	002	Feb 15, 2002	Apr	DISC
>A>			@	EQ 500MG BASE	A065043	001	Feb 15, 2002	Apr	DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV
ZINACEF

>A>	AB	+	COVIS PHARMA	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Apr	CAHN
>D>	AB	+	GLAXOSMITHKLINE	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Apr	CAHN

INJECTABLE; INJECTION
ZINACEF

>A>	AP	+	COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr	CAHN
>A>	AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr	CAHN
>D>	AP	+	GLAXOSMITHKLINE	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr	CAHN
>D>	AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr	CAHN

ZINACEF IN PLASTIC CONTAINER

>A>		+	COVIS PHARMA	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Apr	CAHN
>A>		+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Apr	CAHN
>D>		+	GLAXOSMITHKLINE	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Apr	CAHN
>D>		+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Apr	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL
CETIRIZINE HYDROCHLORIDE

>A>	AA		SILARX	5MG/5ML	A078876	001	May 11, 2012	Apr	NEWA

CICLESONIDE

AEROSOL, METERED; NASAL
ZETONNA

		+	NYCOMED GMBH	0.037MG/INH	N202129	001	Jan 20, 2012	Jan	NEWA

CICLOPIROX

CREAM; TOPICAL
CICLOPIROX

	AB		FOUGERA PHARMS	0.77%	A076435	001	Dec 29, 2004	Jan	CAHN

GEL; TOPICAL
CICLOPIROX

	AB		FOUGERA PHARMS	0.77%	A077896	001	Jun 10, 2008	Jan	CAHN
	AB		GLENMARK GENERICS	0.77%	A091595	001	Feb 29, 2012	Feb	NEWA

SHAMPOO; TOPICAL
CICLOPIROX

	AT		FOUGERA PHARMS	1%	A090146	001	May 25, 2010	Jan	CAHN

SOLUTION; TOPICAL
CICLOPIROX

	AT		MYLAN PHARMS INC	8%	A078567	001	Sep 18, 2007	Feb	CAHN

SUSPENSION; TOPICAL
CICLOPIROX

	AB		FOUGERA PHARMS	0.77%	A076422	001	Aug 06, 2004	Jan	CAHN

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@	TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	Mar	DISC
@		400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	Jan	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	PLIVA	EQ 100MG BASE	A076426	001	Jun 15, 2005	Jan	DISC
@		EQ 250MG BASE	A076426	002	Jun 15, 2005	Jan	DISC
@		EQ 500MG BASE	A076426	003	Jun 15, 2005	Jan	DISC
@		EQ 750MG BASE	A076426	004	Jun 15, 2005	Jan	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

******; ORAL

CIPROFLOXACIN EXTENDED RELEASE

>A>	AB	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701	002	Oct 31, 2007	Apr	NEWA

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

	AP	SANDOZ INC	EQ 2MG BASE/ML	A200159	001	Feb 03, 2012	Jan	NEWA

CISATRACURIUM BESYLATE PRESERVATIVE FREE

	AP	SANDOZ INC	EQ 2MG BASE/ML	A200154	001	Feb 03, 2012	Jan	NEWA
	AP		EQ 10MG BASE/ML	A200154	002	Feb 03, 2012	Jan	NEWA

NIMBEX

	AP	+ ABBOTT	EQ 2MG BASE/ML	N020551	001	Dec 15, 1995	Jan	CFTG

NIMBEX PRESERVATIVE FREE

	AP	+ ABBOTT	EQ 2MG BASE/ML	N020551	003	Dec 15, 1995	Jan	CFTG
	AP	+	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Jan	CFTG

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

>A>	AP	ONCO THERAPIES LTD	1MG/ML	A091062	001	Apr 18, 2012	Apr	NEWA
		@ TEVA PARENTERAL	1MG/ML	A074814	001	May 16, 2000	Mar	DISC

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

	AB	FOUGERA PHARMS	EQ 2% BASE	A065139	001	Dec 27, 2004	Jan	CAHN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

	AB	FOUGERA PHARMS	EQ 1% BASE	A064160	001	Jan 28, 2000	Jan	CAHN

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

	AB	FOUGERA PHARMS	EQ 1% BASE	A065067	001	Jan 31, 2002	Jan	CAHN

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

	AT	FOUGERA PHARMS	EQ 1% BASE	A065254	001	Feb 14, 2006	Jan	CAHN

CLOBAZAM

TABLET; ORAL

ONFI

		LUNDBECK LLC	5MG	N202067	001	Oct 21, 2011	Mar	CAHN
			10MG	N202067	002	Oct 21, 2011	Mar	CAHN
	+		20MG	N202067	003	Oct 21, 2011	Mar	CAHN

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2		FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	Jan	CAHN

TEMOVATE

AB1	+	FOUGERA PHARMS	0.05%	N019322	001	Dec 27, 1985	Jan	CAHN

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	Jan	CAHN

TEMOVATE

AB	+	FOUGERA PHARMS	0.05%	N020337	001	Apr 29, 1994	Jan	CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Jan	CAHN

TEMOVATE

AB	+	FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan	CAHN

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT		FOUGERA PHARMS	0.05%	A075391	001	Feb 08, 1999	Jan	CAHN

TEMOVATE

AT	+	FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990	Jan	CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

AP		MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615	001	Oct 02, 1996	Feb	CAHN
AP	+		5 MG/10 ML (0.5 MG/ML)	N020615	002	Apr 27, 1999	Feb	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

>A>	AB	APOTEX INC	EQ 300MG BASE	A076274	002	May 17, 2012	Apr	NEWA
>A>	AB	AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540	001	May 17, 2012	Apr	NEWA
	AB	DR REDDYS LABS INC	EQ 75MG BASE	A076273	001	Jan 14, 2008	Mar	CMFD
>A>	AB	DR REDDYS LABS LTD	EQ 300MG BASE	A091023	001	May 17, 2012	Apr	NEWA
>A>	AB	GATE PHARMS	EQ 300MG BASE	A091216	001	May 17, 2012	Apr	NEWA
>A>	AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665	001	May 17, 2012	Apr	NEWA
>A>	AB		EQ 300MG BASE	A077665	002	May 17, 2012	Apr	NEWA
>A>	AB	ROXANE	EQ 75MG BASE	A078004	001	May 17, 2012	Apr	NEWA
>A>	AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494	001	May 17, 2012	Apr	NEWA
>A>	AB	TEVA	EQ 75MG BASE	A076999	001	May 17, 2012	Apr	NEWA
>A>	AB	TEVA PHARMS	EQ 300MG BASE	A090625	001	May 17, 2012	Apr	NEWA
>A>	AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844	001	May 17, 2012	Apr	NEWA

PLAVIX

AB		SANOFI AVENTIS US	EQ 75MG BASE	N020839	001	Nov 17, 1997	Mar	CTEC
>D>	+		EQ 300MG BASE	N020839	002	Sep 20, 2007	Apr	CTEC
>A>	AB +		EQ 300MG BASE	N020839	002	Sep 20, 2007	Apr	CTEC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

	@	LUNDBECK LLC	3.75MG	N017105	001		Mar	CAHN
	@		7.5MG	N017105	002		Mar	CAHN
	@		15MG	N017105	003		Mar	CAHN

TABLET; ORAL

TRANXENE

AB		LUNDBECK LLC	3.75MG	N017105	006		Mar	CAHN
AB			7.5MG	N017105	007		Mar	CAHN
AB	+		15MG	N017105	008		Mar	CAHN

TRANXENE SD

	@	LUNDBECK LLC	11.25MG	N017105	005		Mar	CAHN
	@		22.5MG	N017105	004		Mar	CAHN

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

AB		FOUGERA PHARMS	1%	A078338	001	Sep 02, 2008	Jan	CAHN

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

>D>		AZUR PHARMA INTL	12.5MG	N021590	004	May 30, 2007	Apr	CAHN
>D>			25MG	N021590	001	Feb 10, 2004	Apr	CAHN
>D>	@		50MG	N021590	003	Jun 03, 2005	Apr	CAHN
>D>	+		100MG	N021590	002	Feb 10, 2004	Apr	CAHN
>D>			150MG	N021590	005	Jul 09, 2010	Apr	CAHN
>D>			200MG	N021590	006	Jul 09, 2010	Apr	CAHN
>A>		JAZZ	12.5MG	N021590	004	May 30, 2007	Apr	CAHN
>A>			25MG	N021590	001	Feb 10, 2004	Apr	CAHN
>A>	@		50MG	N021590	003	Jun 03, 2005	Apr	CAHN
>A>	+		100MG	N021590	002	Feb 10, 2004	Apr	CAHN
>A>			150MG	N021590	005	Jul 09, 2010	Apr	CAHN
>A>			200MG	N021590	006	Jul 09, 2010	Apr	CAHN

CROMOLYN SODIUM

CONCENTRATE; ORAL

GASTROCROM

AA	+	JAZZ PHARMS COMMERCL	100MG/5ML	N020479	001	Feb 29, 1996	Mar	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
AB			10MG	A077209	001	Oct 04, 2005	Feb	CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

>D>	AP		BAXTER HLTHCARE	500MG/VIAL	N012142	003		Apr	CRLD
>A>	AP	+		500MG/VIAL	N012142	003		Apr	CRLD
>D>	AP			1GM/VIAL	N012142	004	Aug 30, 1982	Apr	CRLD
>A>	AP	+		1GM/VIAL	N012142	004	Aug 30, 1982	Apr	CRLD
>D>	AP			2GM/VIAL	N012142	005	Aug 30, 1982	Apr	CRLD

			INJECTABLE; INJECTION							
			CYTOXAN							
>A>	AP	+	BAXTER HLTHCARE	2GM/VIAL	N012142	005	Aug 30, 1982	Apr	CRLD	
			CYTARABINE							
			INJECTABLE; INJECTION							
			CYTARABINE							
	AP		ONCO THERAPIES LTD	100MG/ML	A201784	001	Jan 30, 2012	Jan	NEWA	
			DACTINOMYCIN							
			INJECTABLE; INJECTION							
			COSMEGEN							
	AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682	001		Mar	CAHN	
			DARUNAVIR ETHANOLATE							
			SUSPENSION; ORAL							
			PREZISTA							
		+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895	001	Dec 16, 2011	Feb	CAHN	
			TABLET; ORAL							
			PREZISTA							
			JANSSEN PRODS	EQ 75MG BASE	N021976	004	Dec 18, 2008	Feb	CAHN	
				EQ 150MG BASE	N021976	005	Dec 18, 2008	Feb	CAHN	
		@		EQ 300MG BASE	N021976	001	Jun 23, 2006	Feb	CAHN	
				EQ 400MG BASE	N021976	003	Oct 21, 2008	Feb	CAHN	
		+		EQ 600MG BASE	N021976	002	Feb 25, 2008	Feb	CAHN	
			DESLORATADINE							
			TABLET; ORAL							
			DESLORATADINE							
>A>	AB		BELCHER PHARMS	5MG	A078355	001	Apr 19, 2012	Apr	NEWA	
	AB		MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012	Jan	NEWA	
			DESMOPRESSIN ACETATE							
			SOLUTION; NASAL							
			DDAVP							
	AB	+	SANOFI AVENTIS US	0.01%	N017922	001		Mar	CFTG	
			DESMOPRESSIN ACETATE							
	AB		SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012	Mar	NEWA	
			DESOGESTREL; ETHINYL ESTRADIOL							
			TABLET; ORAL-28							
			VIORELE							
	AB		GLENMARK GENERICS	.15MG,N/A; 0.02MG,0.01MG	A091346	001	Apr 02, 2012	Mar	NEWA	
			DESONIDE							
			LOTION; TOPICAL							
			DESONIDE							
	AB		FOUGERA PHARMS	0.05%	A075860	001	Mar 19, 2002	Jan	CAHN	
			OINTMENT; TOPICAL							
			DESONIDE							
	AB		FOUGERA PHARMS	0.05%	A075751	001	Mar 12, 2001	Jan	CAHN	
			DESOXIMETASONE							
			CREAM; TOPICAL							
			DESOXIMETASONE							
	AB		FOUGERA PHARMS	0.25%	A078369	001	Jun 29, 2010	Jan	CAHN	

CREAM; TOPICAL
DESOXIMETASONE

>D>	AB	+	TARO	0.05%	A073210	001	Nov 30, 1990	Apr	CTNA
>D>	AB			0.25%	A073193	001	Nov 30, 1990	Apr	CTNA

>A> TOPICORT

>A>		+	TARO	0.05%	A073210	001	Nov 30, 1990	Apr	CTNA
>A>		+		0.25%	A073193	001	Nov 30, 1990	Apr	CTNA
>D>	AB	+	TARO PHARMS NORTH	0.25%	N017856	001		Apr	DISC
>A>		@		0.25%	N017856	001		Apr	DISC

>D> TOPICORT LP

>D>	AB		TARO PHARMS NORTH	0.05%	N018309	001		Apr	DISC
>A>		@		0.05%	N018309	001		Apr	DISC

GEL; TOPICAL

>D> DESOXIMETASONE

>D>	AB		TARO	0.05%	A074904	001	Jul 14, 1998	Apr	CTNA

>A> TOPICORT

>A>	AB	+	TARO	0.05%	A074904	001	Jul 14, 1998	Apr	CTNA
>D>	AB	+	TARO PHARMS NORTH	0.05%	N018586	001	Mar 29, 1982	Apr	DISC
>A>		@		0.05%	N018586	001	Mar 29, 1982	Apr	DISC

OINTMENT; TOPICAL

>D> DESOXIMETASONE

>D>	AB	+	TARO	0.25%	A074286	001	Jun 07, 1996	Apr	CTNA
	AB	+		0.25%	A074286	001	Jun 07, 1996	Mar	CRLD

>A> TOPICORT

>A>		+	TARO	0.25%	A074286	001	Jun 07, 1996	Apr	CTNA
		@	TARO PHARMS NORTH	0.25%	N018763	001	Sep 30, 1983	Mar	DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

	AP	+	APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572	001	Apr 22, 2005	Feb	CRLD

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

>D>	AP		HOSPIRA	5MG/ML	A071584	001	Oct 13, 1987	Apr	DISC
>A>		@		5MG/ML	A071584	001	Oct 13, 1987	Apr	DISC

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

	BX	+	FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002	Jan	CAHN
	AB1	+		0.05%	A075187	001	Mar 30, 1998	Jan	CAHN

OINTMENT; TOPICAL
DIFLORASONE DIACETATE

	AB		FOUGERA PHARMS	0.05%	A075374	001	Apr 27, 1999	Jan	CAHN

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL

	AB		EMCURE PHARMS USA	500MG	A202845	001	Mar 08, 2012	Feb	NEWA
	AB	+	TEVA	500MG	A073673	001	Jul 31, 1992	Feb	CTEC

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION
DILTIAZEM HYDROCHLORIDE

		@	TEVA PARENTERAL	5MG/ML	A074894	001	Aug 26, 1997	Jan	DISC

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
BENADRYL

		@	MCNEIL CONS	50MG/ML	N006146	002		Mar	DISC

BENADRYL PRESERVATIVE FREE

		@	MCNEIL CONS	50MG/ML	N009486	001		Mar	DISC

DIPHENHYDRAMINE HYDROCHLORIDE

>D>	AP		BAXTER HLTHCARE	50MG/ML	A080817	002		Apr	CRLD
>A>	AP	+		50MG/ML	A080817	002		Apr	CRLD

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

		@	TEVA PARENTERAL	5MG/ML	A074952	001	Nov 26, 1997	Jan	DISC

TABLET; ORAL
DIPYRIDAMOLE

	AB		PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Feb	CAHN
	AB			50MG	A040542	002	Apr 21, 2006	Feb	CAHN
	AB			75MG	A040542	003	Apr 21, 2006	Feb	CAHN

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL
DIVALPROEX SODIUM

	AB		DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161	001	Mar 15, 2012	Feb	NEWA
	AB		REDDYS	EQ 500MG VALPROIC ACID	A090070	001	Mar 12, 2012	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

>A>	AP		ACCORD HLTHCARE	20MG/ML (20MG/ML)	N201195	003	Apr 20, 2012	Apr	NEWA
	AP			20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jan	CTEC
>A>	AP			80MG/4ML (20MG/ML)	N201195	004	Apr 20, 2012	Apr	NEWA
	AP			80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jan	CTEC
>A>				160MG/8ML (20MG/ML)	N201195	005	Apr 20, 2012	Apr	NEWA
	AP		APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012	Jan	NEWA
	AP			80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012	Jan	NEWA

TAXOTERE

>D>		+	SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449	003	Aug 03, 2010	Apr	CTEC
>A>	AP	+		20MG/ML (20MG/ML)	N020449	003	Aug 03, 2010	Apr	CTEC
>D>		+		80MG/4ML (20MG/ML)	N020449	004	Aug 02, 2010	Apr	CTEC
>A>	AP	+		80MG/4ML (20MG/ML)	N020449	004	Aug 02, 2010	Apr	CTEC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
COSOPT PF

		+	MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	Feb	NEWA

DOXAZOSIN MESYLATE

TABLET; ORAL
DOXAZOSIN MESYLATE

	@ NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000	Feb	DISC	
	@	EQ 2MG BASE	A075609	002	Oct 18, 2000	Feb	DISC	
	@	EQ 4MG BASE	A075609	003	Oct 18, 2000	Feb	DISC	
	@	EQ 8MG BASE	A075609	004	Oct 18, 2000	Feb	DISC	

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL
ZONALON

+	FOUGERA PHARMS	5%	N020126	001	Apr 01, 1994	Jan	CAHN	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

AP	ONCO THERAPIES LTD	2MG/ML	A200901	001	Feb 14, 2012	Jan	NEWA	
AP	SUN PHARM INDS	2MG/ML	A091418	001	Feb 15, 2012	Jan	NEWA	

INJECTABLE, LIPOSOMAL; INJECTION
DOXIL

+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jan	CAHN	
+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jan	CAHN	

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

	@ SANDOZ INC	EQ 50MG BASE	A065032	001	Jun 30, 2000	Mar	DISC	
	@	EQ 100MG BASE	A065032	002	Jun 30, 2000	Mar	DISC	

TABLET; ORAL
DOXYCYCLINE

	@ SANDOZ INC	EQ 50MG BASE	A065353	001	Nov 27, 2006	Mar	DISC	
	@	EQ 75MG BASE	A065353	002	Nov 27, 2006	Mar	DISC	
	@	EQ 100MG BASE	A065353	003	Nov 27, 2006	Mar	DISC	

DOXYCYCLINE HYCLATE

TABLET; ORAL
DOXYCYCLINE HYCLATE

>D>	@ LARKEN LABS	EQ 20MG BASE	A065287	001	Feb 28, 2006	Apr	CMFD	
>A> AB		EQ 20MG BASE	A065287	001	Feb 28, 2006	Apr	CMFD	

TABLET, DELAYED RELEASE; ORAL
DORYX

AB +	MAYNE PHARMA	EQ 150MG BASE	N050795	003	Jun 20, 2008	Jan	CTEC	

DOXYCYCLINE HYCLATE

AB	MYLAN PHARMS INC	EQ 150MG BASE	A091052	001	Feb 08, 2012	Jan	NEWA	

DROSPIRENONE; ESTRADIOL

TABLET; ORAL
ANGELIQ

	BAYER HLTHCARE	0.25MG;0.5MG	N021355	001	Feb 29, 2012	Feb	NEWA	

ECONAZOLE NITRATE

CREAM; TOPICAL
ECONAZOLE NITRATE

AB +	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Jan	CAHN	

>A>	EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE								
>A>	TABLET; ORAL								
>A>	COMPLERA								
>A>	+ GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG		N202123	001	Aug 10, 2011	Apr	CAIN	
>D>	EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE								
>D>	TABLET; ORAL								
>D>	COMPLERA								
>D>	+ GILEAD SCIENCES INC	200MG;25MG;300MG		N202123	001	Aug 10, 2011	Apr	CAIN	
	ENALAPRIL MALEATE								
	TABLET; ORAL								
	ENALAPRIL MALEATE								
	@ SANDOZ INC	2.5MG		A075621	001	Aug 22, 2000	Feb	DISC	
	@	2.5MG		A075496	001	Aug 22, 2000	Jan	DISC	
	@	5MG		A075621	002	Aug 22, 2000	Feb	DISC	
	@	5MG		A075496	002	Aug 22, 2000	Jan	DISC	
	@	10MG		A075621	003	Aug 22, 2000	Feb	DISC	
	@	10MG		A075459	001	Aug 22, 2000	Jan	DISC	
	@	20MG		A075621	004	Aug 22, 2000	Feb	DISC	
	@	20MG		A075459	002	Aug 22, 2000	Jan	DISC	
	ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE								
	TABLET; ORAL								
	ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE								
	@ SANDOZ INC	5MG;12.5MG		A076116	001	Sep 19, 2001	Mar	DISC	
	@	10MG;25MG		A076116	002	Sep 19, 2001	Mar	DISC	
	EPINASTINE HYDROCHLORIDE								
	SOLUTION/DROPS; OPHTHALMIC								
	EPINASTINE HYDROCHLORIDE								
AT	LUITPOLD	0.05%		A090951	001	Oct 31, 2011	Mar	CAHN	
	EPINEPHRINE								
	INJECTABLE; IM-SC								
	ADRENACLICK								
BX	+ COREPHARMA	EQ 0.15MG /DELIVERY		N020800	003	Nov 25, 2009	Mar	CAHN	
BX	+	EQ 0.3MG /DELIVERY		N020800	004	Nov 25, 2009	Mar	CAHN	
	TWINJECT 0.15								
BX	+ COREPHARMA	EQ 0.15MG /DELIVERY		N020800	002	May 28, 2004	Mar	CAHN	
	TWINJECT 0.3								
BX	+ COREPHARMA	EQ 0.3MG /DELIVERY		N020800	001	May 30, 2003	Mar	CAHN	
	EPIRUBICIN HYDROCHLORIDE								
	INJECTABLE; INJECTION								
	EPIRUBICIN HYDROCHLORIDE								
AP	CIPLA LTD	50MG/25ML (2MG/ML)		A065361	001	Oct 22, 2007	Mar	CAHN	
AP		200MG/100ML (2MG/ML)		A065361	002	Oct 22, 2007	Mar	CAHN	
AP	HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)		A090075	001	Mar 25, 2010	Mar	CAHN	
AP		200MG/100ML (2MG/ML)		A090075	002	Mar 25, 2010	Mar	CAHN	
AP	ONCO THERAPIES LTD	50MG/25ML (2MG/ML)		A091599	001	Mar 12, 2012	Mar	NEWA	
AP		200MG/100ML (2MG/ML)		A091599	002	Mar 12, 2012	Mar	NEWA	

ERYTHROMYCIN

GEL; TOPICAL

ERYTHROMYCIN

AT		FOUGERA PHARMS	2%	A064184	001	Sep 30, 1997	Jan	CAHN

SOLUTION; TOPICAL

C-SOLVE-2

AT		FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Jan	CMFD

SWAB; TOPICAL

ERYCETTE

>A>		@ JOHNSON AND JOHNSON	2%	N050594	001	Feb 15, 1985	Apr	CAHN
>D>		@ ORTHO JANSSEN	2%	N050594	001	Feb 15, 1985	Apr	CAHN

ERYTHROMYCIN

AT	+	FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006	Jan	CAHN

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA		AMNEAL PHARMS	EQ 5MG BASE/5ML	A202227	001	Mar 14, 2012	Feb	NEWA
AA		AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML	A079062	001	Apr 02, 2012	Mar	NEWA
>A>	AA	TARO	EQ 5MG BASE/5ML	A079121	001	May 03, 2012	Apr	NEWA

LEXAPRO

AA	+	FOREST LABS	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Feb	CFTG

TABLET; ORAL

ESCITALOPRAM OXALATE

AB		IVAX SUB TEVA PHARMS	EQ 5MG BASE	A076765	001	Mar 14, 2012	Feb	NEWA
AB			EQ 10MG BASE	A076765	002	Mar 14, 2012	Feb	NEWA
AB			EQ 20MG BASE	A076765	003	Mar 14, 2012	Feb	NEWA

LEXAPRO

AB		FOREST LABS	EQ 5MG BASE	N021323	001	Aug 14, 2002	Feb	CFTG
AB			EQ 10MG BASE	N021323	002	Aug 14, 2002	Feb	CFTG
AB	+		EQ 20MG BASE	N021323	003	Aug 14, 2002	Feb	CFTG

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB		TEVA PHARMS USA	0.5MG;0.1MG	A200747	001	Mar 08, 2012	Feb	NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

FALMINA

AB1		NOVAST LABS LTD	0.02MG;0.1MG	A090721	001	Mar 28, 2012	Mar	NEWA

MARLISSA

AB		GLENMARK GENERICS	0.03MG;0.15MG	A091452	001	Feb 29, 2012	Feb	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

ALYACEN 1/35

AB		GLENMARK GENERICS	0.035MG;1MG	A091634	001	Jan 19, 2012	Jan	NEWA

ALYACEN 7/7/7

AB		GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636	001	Jan 19, 2012	Jan	NEWA

WERA

AB		NOVAST LABS LTD	0.035MG;0.5MG	A091204	001	Mar 27, 2012	Mar	NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28
NORGESTIMATE AND ETHINYL ESTRADIOL

AB		GLENMARK GENERICS	0.035MG;0.25MG	A200538	001	Apr 05, 2012	Mar	NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28
ELINEST

AB		NOVAST LABS LTD	0.03MG;0.3MG	A091105	001	Mar 28, 2012	Mar	NEWA

ETODOLAC

TABLET; ORAL
ETODOLAC

AB		PROSAM LABS	400MG	A074819	001	Feb 28, 1997	Feb	CMFD
AB			500MG	A074819	002	Apr 28, 1998	Feb	CMFD

ETOPOSIDE

CAPSULE; ORAL
VEPESID

		@ CORDEN PHARMA	50MG	N019557	001	Dec 30, 1986	Feb	CAHN
		@	100MG	N019557	002	Dec 30, 1986	Feb	CAHN

INJECTABLE; INJECTION
ETOPOSIDE

AP	+	APP PHARMS LLC	20MG/ML	A074983	001	Sep 30, 1998	Mar	CRLD
AP		BEDFORD	20MG/ML	A074290	001	Jul 17, 1995	Mar	CRLD

VEPESID

		@ CORDEN PHARMA	20MG/ML	N018768	001	Nov 10, 1983	Feb	CAHN

ETRAVIRINE

TABLET; ORAL
INTELENCE

		JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012	Mar	NEWA
			100MG	N022187	001	Jan 18, 2008	Feb	CAHN
	+		200MG	N022187	002	Dec 22, 2010	Feb	CAHN

EVEROLIMUS

TABLET; ORAL
AFINITOR

>A>		NOVARTIS	7.5MG	N022334	004	Mar 30, 2012	Apr	NEWA

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS
BYDUREON

	+	AMYLIN	2MG/VIAL	N022200	001	Jan 27, 2012	Jan	NEWA

EZETIMIBE

TABLET; ORAL
ZETIA

	+	MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Feb	CAHN
	+	MSP SINGAPORE	10MG	N021445	001	Oct 25, 2002	Jan	CAHN

EZETIMIBE; SIMVASTATIN

TABLET; ORAL
VYTORIN

		MSD INTL	10MG;10MG	N021687	001	Jul 23, 2004	Jan	CAHN

		TABLET; ORAL						
		VYTORIN						
		MSD INTL	10MG;20MG	N021687	002	Jul 23, 2004	Jan	CAHN
			10MG;40MG	N021687	003	Jul 23, 2004	Jan	CAHN
	+		10MG;80MG	N021687	004	Jul 23, 2004	Jan	CAHN
		FAMCICLOVIR						
		TABLET; ORAL						
		FAMCICLOVIR						
	AB	MACLEODS PHARMS LTD	125MG	A201022	001	Jan 12, 2012	Jan	NEWA
	AB		250MG	A201022	002	Jan 12, 2012	Jan	NEWA
	AB		500MG	A201022	003	Jan 12, 2012	Jan	NEWA
		FAMOTIDINE						
		TABLET; ORAL						
		PEPCID						
	AB	MARATHON PHARMS	20MG	N019462	001	Oct 15, 1986	Jan	CAHN
	AB	+	40MG	N019462	002	Oct 15, 1986	Jan	CAHN
		TABLET, ORALLY DISINTEGRATING; ORAL						
		FLUXID						
		@ UCB INC	20MG	N021712	001	Sep 24, 2004	Jan	CAHN
		@	40MG	N021712	002	Sep 24, 2004	Jan	CAHN
		FEBUXOSTAT						
		TABLET; ORAL						
		ULORIC						
>D>		TAKEDA PHARMS	40MG	N021856	001	Feb 13, 2009	Apr	CAHN
>D>	+		80MG	N021856	002	Feb 13, 2009	Apr	CAHN
>A>		TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009	Apr	CAHN
>A>	+		80MG	N021856	002	Feb 13, 2009	Apr	CAHN
		FENOFIBRATE						
		CAPSULE; ORAL						
		ANTARA (MICRONIZED)						
	AB	LUPIN ATLANTIS	43MG	N021695	001	Nov 30, 2004	Feb	CFTG
	AB	+	130MG	N021695	003	Nov 30, 2004	Feb	CFTG
		FENOFIBRATE (MICRONIZED)						
	AB	DR REDDYS LABS SA	43MG	A090859	001	Mar 01, 2012	Feb	NEWA
	AB		130MG	A090859	002	Mar 01, 2012	Feb	NEWA
		TABLET; ORAL						
		FENOFIBRATE						
	AB	+ IMPAX LABS	160MG	A076509	002	Mar 26, 2008	Mar	CRLD
		@ TEVA	54MG	A076433	001	May 13, 2005	Mar	DISC
		@	160MG	A076433	002	May 13, 2005	Mar	DISC
	AB	VALEANT INTL	48MG	A090715	001	Apr 05, 2012	Mar	NEWA
	AB		145MG	A090715	002	Apr 05, 2012	Mar	NEWA
		FENTANYL						
		SPRAY; SUBLINGUAL						
		SUBSYS						
		INSYS THERAP	0.1MG	N202788	001	Jan 04, 2012	Mar	CPOT
			0.1MCG	N202788	001	Jan 04, 2012	Jan	NEWA
			0.2MG	N202788	002	Jan 04, 2012	Mar	CPOT
			0.2MCG	N202788	002	Jan 04, 2012	Jan	NEWA
	+		0.4MG	N202788	003	Jan 04, 2012	Mar	CPOT
	+		0.4MCG	N202788	003	Jan 04, 2012	Jan	NEWA

SPRAY; SUBLINGUAL
SUBSYS

	INSYS THERAP	0.6MG	N202788	004	Jan 04, 2012	Mar	CPOT
		0.6MCG	N202788	004	Jan 04, 2012	Jan	NEWA
		0.8MG	N202788	005	Jan 04, 2012	Mar	CPOT
		0.8MCG	N202788	005	Jan 04, 2012	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL
LAZANDA

	ARCHIMEDES	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Jan	CPOT
+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Jan	CPOT

TROCHE/LOZENGE; TRANSMUCOSAL
FENTANYL CITRATE

AB	PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009	Feb	CAHN
AB		EQ 0.4MG BASE	A077312	002	Oct 30, 2009	Feb	CAHN
AB		EQ 0.6MG BASE	A077312	003	Oct 30, 2009	Feb	CAHN
AB		EQ 0.8MG BASE	A077312	004	Oct 30, 2009	Feb	CAHN
AB		EQ 1.2MG BASE	A077312	005	Oct 30, 2009	Feb	CAHN
AB		EQ 1.6MG BASE	A077312	006	Oct 30, 2009	Feb	CAHN

>A> FLORBETAPIR F-18

>A> SOLUTION; INTRAVENOUS
>A> AMYVID

>A> +	AVID RADIOPHARMS INC	10-30ML (13.5-51MCI/ML)	N202008	002	Apr 06, 2012	Apr	NEWA
>A> +		10-50ML (13.5-51CMI/ML)	N202008	003	Apr 06, 2012	Apr	NEWA
>A> +		10ML (13.5-51MCI/ML)	N202008	001	Apr 06, 2012	Apr	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012	Jan	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698	001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078698	002	Jan 30, 2012	Jan	NEWA

TABLET; ORAL
FLUCONAZOLE

@	PLIVA	50MG	A076424	001	Jul 29, 2004	Feb	DISC
@		100MG	A076424	002	Jul 29, 2004	Feb	DISC
@		150MG	A076424	003	Jul 29, 2004	Feb	DISC
@		200MG	A076424	004	Jul 29, 2004	Feb	DISC
>D> AB	RANBAXY	50MG	A076386	001	Jul 29, 2004	Apr	DISC
>D> AB		100MG	A076386	002	Jul 29, 2004	Apr	DISC
>D> AB		150MG	A076386	003	Jul 29, 2004	Apr	DISC
>D> AB		200MG	A076386	004	Jul 29, 2004	Apr	DISC
>A> @	RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004	Apr	DISC
>A> @		100MG	A076386	002	Jul 29, 2004	Apr	DISC
>A> @		150MG	A076386	003	Jul 29, 2004	Apr	DISC
>A> @		200MG	A076386	004	Jul 29, 2004	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION
FLUDARA

@	GENZYME CORP	50MG/VIAL	N020038	001	Apr 18, 1991	Mar	DISC

INJECTABLE; INJECTION
FLUDARABINE PHOSPHATE

AP	+	HOSPIRA	50MG/VIAL	A077790	001	Apr 06, 2007	Mar	CRLD	

FLUMAZENIL

INJECTABLE; INJECTION
FLUMAZENIL

	@	TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Jan	DISC	
	@		1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Jan	DISC	

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC
FLUOCINOLONE ACETONIDE

AT		IDENTI PHARMS INC	0.01%	A091306	001	Oct 17, 2011	Jan	CPOT	

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE EMULSIFIED BASE

AB2		FOUGERA PHARMS	0.05%	A076586	001	Jun 23, 2004	Jan	CAHN	

OINTMENT; TOPICAL
FLUOCINONIDE

AB		FOUGERA PHARMS	0.05%	A074905	001	Aug 26, 1997	Jan	CAHN	

FLUOROURACIL

CREAM; TOPICAL
FLUOROPLEX

	+	AQUA PHARMS	1%	N016988	001		Jan	CAHN	

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
PROZAC

>A>	AB1		ELI LILLY AND CO	EQ 10MG BASE	N018936	006	Dec 23, 1992	Apr	CAHN
>A>	AB1			EQ 20MG BASE	N018936	001	Dec 29, 1987	Apr	CAHN
>A>	AB	+		EQ 40MG BASE	N018936	003	Jun 15, 1999	Apr	CAHN
>A>		@		EQ 60MG BASE	N018936	004	Jun 15, 1999	Apr	CAHN
>D>	AB1		LILLY	EQ 10MG BASE	N018936	006	Dec 23, 1992	Apr	CAHN
>D>	AB1			EQ 20MG BASE	N018936	001	Dec 29, 1987	Apr	CAHN
>D>	AB	+		EQ 40MG BASE	N018936	003	Jun 15, 1999	Apr	CAHN
>D>		@		EQ 60MG BASE	N018936	004	Jun 15, 1999	Apr	CAHN

SARAFEM

>A>	AB2		ELI LILLY AND CO	EQ 10MG BASE	N018936	007	Jul 06, 2000	Apr	CAHN
>A>	AB2	+		EQ 20MG BASE	N018936	008	Jul 06, 2000	Apr	CAHN
>D>	AB2		LILLY	EQ 10MG BASE	N018936	007	Jul 06, 2000	Apr	CAHN
>D>	AB2	+		EQ 20MG BASE	N018936	008	Jul 06, 2000	Apr	CAHN

FLURANDRENOLIDE

CREAM; TOPICAL
CORDRAN SP

>D>		@	WATSON PHARMS	0.05%	N012806	002		Apr	CMFD
>A>				0.05%	N012806	002		Apr	CMFD

FLUTAMIDE

CAPSULE; ORAL
FLUTAMIDE

AB	+	IVAX SUB TEVA PHARMS	125MG	A075780	001	Sep 19, 2001	Mar	CRLD	
AB		SANDOZ INC	125MG	A075818	001	Sep 18, 2001	Mar	CRLD	

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	0.05%	N019958	001	Dec 18, 1990	Jan	CAHN

FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	0.05%	A076451	001	May 14, 2004	Jan	CAHN

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	0.005%	A076300	001	May 14, 2004	Jan	CAHN

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB		MYLAN PHARMS INC	EQ 20MG BASE	A090595	001	Apr 11, 2012	Mar	NEWA
AB			EQ 40MG BASE	A090595	002	Apr 11, 2012	Mar	NEWA

LESCOL

AB		NOVARTIS	EQ 20MG BASE	N020261	001	Dec 31, 1993	Mar	CFTG
AB	+		EQ 40MG BASE	N020261	002	Dec 31, 1993	Mar	CFTG

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

>D>	AB	RANBAXY	10MG	A076580	001	Apr 23, 2004	Apr	DISC
>D>	AB		20MG	A076580	002	Apr 23, 2004	Apr	DISC
>D>	AB		40MG	A076580	003	Apr 23, 2004	Apr	DISC
>A>		@ RANBAXY LABS LTD	10MG	A076580	001	Apr 23, 2004	Apr	DISC
>A>		@	20MG	A076580	002	Apr 23, 2004	Apr	DISC
>A>		@	40MG	A076580	003	Apr 23, 2004	Apr	DISC

MONOPRIL

		@ BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Mar	DISC
		@	20MG	N019915	003	May 16, 1991	Mar	DISC
		@	40MG	N019915	004	Mar 28, 1995	Mar	DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

		@ TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	Mar	DISC

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

	AA	AMNEAL PHARMS	250MG/5ML	A202024	001	Mar 23, 2012	Mar	NEWA
>A>	AA	KIEL	250MG/5ML	A076403	001	May 01, 2012	Apr	NEWA

GANCICLOVIR

CAPSULE; ORAL

>D>		GANCICLOVIR							
>D>		RANBAXY	250MG	A076457	001	Jun 27, 2003	Apr	DISC
>D>	+		500MG	A076457	002	Jun 27, 2003	Apr	DISC
>A>		@ RANBAXY LABS LTD	250MG	A076457	001	Jun 27, 2003	Apr	DISC
>A>		@	500MG	A076457	002	Jun 27, 2003	Apr	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

>D>			GEMCITABINE						
>D>		+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Apr	CTNA
>D>		+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Apr	CTNA
>D>		+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Apr	CTNA
>A>			GEMCITABINE HYDROCHLORIDE						
>A>		+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Apr	CTNA
>A>		+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Apr	CTNA
>A>		+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Apr	CTNA

GLIMEPIRIDE

TABLET; ORAL

			GLIMEPIRIDE						
>D>	AB		RANBAXY	1MG	A076875	001	Oct 06, 2005	Apr	DISC
>D>	AB			2MG	A076875	002	Oct 06, 2005	Apr	DISC
>D>	AB			4MG	A076875	003	Oct 06, 2005	Apr	DISC
>D>	AB			8MG	A076875	004	Oct 06, 2005	Apr	DISC
>A>		@	RANBAXY LABS LTD	1MG	A076875	001	Oct 06, 2005	Apr	DISC
>A>		@		2MG	A076875	002	Oct 06, 2005	Apr	DISC
>A>		@		4MG	A076875	003	Oct 06, 2005	Apr	DISC
>A>		@		8MG	A076875	004	Oct 06, 2005	Apr	DISC

GLYCOPYRROLATE

TABLET; ORAL

			GLYCOPYRROLATE						
	AA		NEXGEN PHARMA	1.5MG	A091522	001	Mar 12, 2012	Feb	NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

			GRANISETRON HYDROCHLORIDE						
	AP		CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	Mar	CAHN
	AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	Mar	CAHN
	AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	Mar	CAHN
			GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
>D>	AP		APP PHARMS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096	001	Jun 30, 2008	Apr	CRLD
>A>	AP	+	APP PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096	001	Jun 30, 2008	Apr	CRLD
>D>	AP	+	TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	Apr	DISC
>A>		@		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	Apr	DISC

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

			GRIFULVIN V						
	AB	+	VALEANT PHARM NORTH	125MG/5ML	A062483	001	Jan 26, 1984	Feb	CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL

			HALOBETASOL PROPIONATE						
	AB		FOUGERA PHARMS	0.05%	A077001	001	Dec 16, 2004	Jan	CAHN

OINTMENT; TOPICAL

			HALOBETASOL PROPIONATE						
	AB		FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004	Jan	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985	Mar	DISC	

HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983	Mar	DISC	

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985	Mar	DISC	
@		10,000 UNITS/100ML	N018814	004	Jul 02, 1987	Mar	DISC	

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	LANNETT HOLDINGS INC	12.5MG	A091662	001	Jan 27, 2012	Jan	NEWA	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

AB	+	SANOFI AVENTIS	12.5MG;150MG	N020758	002	Sep 30, 1997	Mar	CFTG	
AB	+		12.5MG;300MG	N020758	003	Aug 31, 1998	Mar	CFTG	
	+		12.5MG;300MG	N020758	003	Aug 31, 1998	Feb	CRLD	

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		TEVA	12.5MG;150MG	A077369	001	Mar 30, 2012	Mar	NEWA	
AB			12.5MG;300MG	A077369	002	Mar 30, 2012	Mar	NEWA	
>D>			25MG;300MG	A077369	003	Mar 30, 2012	Apr	DISC	
>A>		@	25MG;300MG	A077369	003	Mar 30, 2012	Apr	DISC	
			25MG;300MG	A077369	003	Mar 30, 2012	Mar	NEWA	

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;50MG	A091617	001	Feb 17, 2012	Feb	NEWA	
AB		12.5MG;100MG	A091617	002	Feb 17, 2012	Feb	NEWA	
AB		25MG;100MG	A091617	003	Feb 17, 2012	Feb	NEWA	

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

	ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jan	CMFD	
		12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jan	CMFD	
>D>		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Apr	CRLD	
>A>	+	12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Apr	CRLD	
		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jan	CMFD	

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	50MG;100MG	A076792	003	Aug 20, 2004	Jan	CTEC	
AB	SUN PHARM INDS	25MG;50MG	A090654	001	Jan 19, 2012	Jan	NEWA	
AB		25MG;100MG	A090654	002	Jan 19, 2012	Jan	NEWA	
AB		50MG;100MG	A090654	003	Jan 19, 2012	Jan	NEWA	

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

		@ PADDOCK LLC	12.5MG;7.5MG	A090096	001	Sep 25, 2008	Jan	DISC
		@	12.5MG;15MG	A090096	002	Sep 25, 2008	Jan	DISC
		@	25MG;15MG	A090096	003	Sep 25, 2008	Jan	DISC

HYDROCORTISONE

LOTION; TOPICAL
HYDROCORTISONE

AT	+	FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000	Jan	CAHN

OINTMENT; TOPICAL
HYDROCORTISONE

AT	+	FOUGERA PHARMS	1%	A080692	001		Jan	CAHN

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL
CARMOL HC

AT		FOUGERA PHARMS	1%;10%	A080505	001		Jan	CAHN

HYDROCORTISONE VALERATE

CREAM; TOPICAL
HYDROCORTISONE VALERATE

AB	+	TARO	0.2%	A075042	001	Aug 25, 1998	Mar	CRLD

WESTCORT

		@ RANBAXY	0.2%	N017950	001		Mar	DISC

OINTMENT; TOPICAL
HYDROCORTISONE VALERATE

AB		FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001	Jan	CAHN

HYDROFLUMETHIAZIDE

TABLET; ORAL
SALURON

AB	+	SHIRE LLC	50MG	N011949	001		Jan	CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL
HYDROXYZINE HYDROCHLORIDE

		@ STI PHARMA LLC	10MG/5ML	A086880	001		Feb	CAHN

IBANDRONATE SODIUM

TABLET; ORAL
BONIVA

AB	+	HOFFMANN LA ROCHE	EQ 150MG BASE	N021455	002	Mar 24, 2005	Mar	CFTG

IBANDRONATE SODIUM

AB		APOTEX INC	EQ 150MG BASE	A078948	001	Mar 19, 2012	Mar	NEWA
>A> AB		DR REDDYS LABS LTD	EQ 150MG BASE	A078997	001	Apr 30, 2012	Apr	NEWA
AB		MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012	Mar	NEWA
AB		ORCHID HLTHCARE	EQ 150MG BASE	A078998	001	Mar 19, 2012	Mar	NEWA
AB		WATSON LABS INC	EQ 150MG BASE	A079003	001	Mar 20, 2012	Mar	NEWA

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar	CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

@	TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002	Mar	DISC
@		10MG/VIAL	A065037	002	May 01, 2002	Mar	DISC
@		20MG/VIAL	A065037	001	May 01, 2002	Mar	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB	PROSAM LABS	10MG	A040753	001	Feb 28, 2008	Feb	CMFD
AB		25MG	A040752	001	Feb 28, 2008	Feb	CMFD
AB		50MG	A040751	001	Feb 28, 2008	Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	APOTEX INC	5%	A091308	001	Apr 06, 2012	Mar	NEWA
AB	FOUGERA PHARMS	5%	A078548	001	Feb 25, 2010	Jan	CAHN
AB	GLENMARK GENERICS	5%	A201994	001	Mar 06, 2012	Feb	NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+ LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985	Mar	CAHN

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

	LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	Jan	NEWA
+		0.05%	N202833	002	Jan 23, 2012	Jan	NEWA

IRBESARTAN

TABLET; ORAL

AVAPRO

AB	SANOFI AVENTIS US	75MG	N020757	001	Sep 30, 1997	Mar	CFTG
AB		150MG	N020757	002	Sep 30, 1997	Mar	CFTG
AB	+	300MG	N020757	003	Sep 30, 1997	Mar	CFTG

IRBESARTAN

AB	TEVA PHARMS	75MG	A077159	001	Mar 30, 2012	Mar	NEWA
AB		150MG	A077159	002	Mar 30, 2012	Mar	NEWA
AB		300MG	A077159	003	Mar 30, 2012	Mar	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	CIPLA LTD	40MG/2ML (20MG/ML)	A077219	001	Feb 20, 2008	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A077219	002	Feb 20, 2008	Mar	CAHN
AP	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771	001	Feb 14, 2012	Jan	NEWA

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

AP	EMCURE PHARMS LTD	100MG/5ML (20MG/ML)	A200771	002	Feb 14, 2012	Jan	NEWA
AP	HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016	001	Jan 28, 2009	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A090016	002	Jan 28, 2009	Mar	CAHN
	@ TEVA PARENTERAL	500MG/25ML (20MG/ML)	A090101	001	Nov 26, 2008	Mar	DISC

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

	@ SKYEPHARMA AG	60MG	A075166	001	Oct 07, 1999	Jan	DISC

ISOTRETINOIN

CAPSULE; ORAL
MYORISAN

AB	DOUGLAS PHARMS	10MG	A076485	001	Jan 19, 2012	Jan	NEWA
AB		20MG	A076485	002	Jan 19, 2012	Jan	NEWA
AB		40MG	A076485	003	Jan 19, 2012	Jan	NEWA

IVACAFTOR

TABLET; ORAL
KALYDECO

+	VERTEX PHARMS	150MG	N203188	001	Jan 31, 2012	Jan	NEWA

IVERMECTIN

LOTION; TOPICAL
SKLICE

+	SANOFI PASTEUR	0.5%	N202736	001	Feb 07, 2012	Feb	NEWA

KETOCONAZOLE

CREAM; TOPICAL
KETOCONAZOLE

AB	FOUGERA PHARMS	2%	A076294	001	Apr 28, 2004	Jan	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION
LABETALOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	5MG/ML	A090699	001	Apr 03, 2012	Mar	NEWA

LACTULOSE

SOLUTION; ORAL
LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090503	001	Jan 25, 2012	Jan	NEWA

SOLUTION; ORAL, RECTAL
LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090502	001	Jan 25, 2012	Jan	NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
LAMIVUDINE AND ZIDOVUDINE

>A>	AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418	001	May 15, 2012	Apr	NEWA
>A>	AB	LUPIN LTD	150MG;300MG	A090246	001	May 15, 2012	Apr	NEWA

LAMOTRIGINE

TABLET; ORAL
LAMOTRIGINE

>A>	AB		GLENMARK GENERICS	25MG	A090169	001	May 12, 2012	Apr	NEWA
>A>	AB			100MG	A090169	002	May 12, 2012	Apr	NEWA
>A>	AB			150MG	A090169	003	May 12, 2012	Apr	NEWA
>A>	AB			200MG	A090169	004	May 12, 2012	Apr	NEWA

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS
SOMATULINE DEPOT

>A>		+	IPSEN INC	EQ 60MG BASE	N022074	001	Aug 30, 2007	Apr	CAHN
>A>		+		EQ 90MG BASE	N022074	002	Aug 30, 2007	Apr	CAHN
>A>		+		EQ 120MG BASE	N022074	003	Aug 30, 2007	Apr	CAHN
>D>		+	IPSEN PHARMS	EQ 60MG BASE	N022074	001	Aug 30, 2007	Apr	CAHN
>D>		+		EQ 90MG BASE	N022074	002	Aug 30, 2007	Apr	CAHN
>D>		+		EQ 120MG BASE	N022074	003	Aug 30, 2007	Apr	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID

	AB		TAKEDA PHARMS USA	15MG	N020406	001	May 10, 1995	Mar	CAHN
	AB	+		30MG	N020406	002	May 10, 1995	Mar	CAHN

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL
LANSOPRAZOLE

			@ TEVA PHARMS	15MG	A078730	001	Oct 15, 2010	Mar	DISC
			@	30MG	A078730	002	Oct 15, 2010	Mar	DISC

PREVACID

			TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002	Mar	CTEC
		+		30MG	N021428	002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL
FOSRENOL

			@ SHIRE LLC	EQ 250MG BASE	N021468	001	Oct 26, 2004	Feb	CAHN
				EQ 500MG BASE	N021468	002	Oct 26, 2004	Feb	CAHN
				EQ 750MG BASE	N021468	003	Nov 23, 2005	Feb	CAHN
		+		EQ 1GM BASE	N021468	004	Nov 23, 2005	Feb	CAHN

LETROZOLE

TABLET; ORAL
LETROZOLE

>A>	AB		APOTEX INC	2.5MG	A091303	001	Apr 19, 2012	Apr	NEWA

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

			@ TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993	Mar	DISC

LEVETIRACETAM

INJECTABLE; IV (INFUSION)
LEVETIRACETAM

	AP		HOSPIRA INC	500MG/ML (100MG/ML)	A202869	001	Apr 06, 2012	Mar	NEWA
	AP		PHARMAFORCE	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012	Jan	NEWA

		SOLUTION; ORAL							
		LEVETIRACETAM							
	AA	HI-TECH PHARMACAL	100MG/ML	A090601	001	Feb 28, 2012	Feb	NEWA	
	AA	VINTAGE PHARMS	100MG/ML	A090079	001	Apr 11, 2012	Mar	NEWA	
		TABLET; ORAL							
		LEVETIRACETAM							
>A>	AB	WATSON LABS INC	250MG	A078797	002	Jan 15, 2009	Apr	NEWA	
>A>	AB		500MG	A078797	003	Jan 15, 2009	Apr	NEWA	
>A>	AB		750MG	A078797	004	Jan 15, 2009	Apr	NEWA	
		LEVOFLOXACIN							
		TABLET; ORAL							
		LEVOFLOXACIN							
	AB	CIPLA LTD	250MG	A076890	001	Mar 30, 2012	Mar	NEWA	
	AB		500MG	A076890	002	Mar 30, 2012	Mar	NEWA	
	AB		750MG	A076890	003	Mar 30, 2012	Mar	NEWA	
	AB	MACLEODS PHARMS LTD	250MG	A200839	001	Mar 22, 2012	Mar	NEWA	
	AB		500MG	A200839	002	Mar 22, 2012	Mar	NEWA	
	AB		750MG	A200839	003	Mar 22, 2012	Mar	NEWA	
	AB	ORCHID HLTHCARE	250MG	A202200	001	Jan 30, 2012	Jan	NEWA	
	AB		500MG	A202200	002	Jan 30, 2012	Jan	NEWA	
	AB		750MG	A202200	003	Jan 30, 2012	Jan	NEWA	
		LIDOCAINE; PRILOCAINE							
		CREAM; TOPICAL							
		LIDOCAINE AND PRILOCAINE							
	AB	FOUGERA PHARMS	2.5%;2.5%	A076453	001	Aug 18, 2003	Jan	CAHN	
		LINAGLIPTIN; METFORMIN HYDROCHLORIDE							
		TABLET; ORAL							
		JENTADUETO							
		BOEHRINGER INGELHEIM	2.5MG;500MG	N201281	001	Jan 30, 2012	Jan	NEWA	
			2.5MG;850MG	N201281	002	Jan 30, 2012	Jan	NEWA	
	+		2.5MG;1GM	N201281	003	Jan 30, 2012	Jan	NEWA	
		LORAZEPAM							
		CONCENTRATE; ORAL							
		LORAZEPAM							
	AA	HI-TECH PHARMA CO	2MG/ML	A200169	001	Jan 30, 2012	Jan	NEWA	
>A>		LUCINACTANT							
>A>		SUSPENSION; INTRATRACHEAL							
>A>		SURFAXIN							
>A>	+	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	Apr	NEWA	
		LURASIDONE HYDROCHLORIDE							
		TABLET; ORAL							
		LATUDA							
>D>		SUNOVION	40MG	N200603	001	Oct 28, 2010	Apr	CRLD	
>D>	+		80MG	N200603	002	Oct 28, 2010	Apr	CRLD	
>A>		SUNOVION PHARMS INC	20MG	N200603	003	Dec 07, 2011	Apr	NEWA	
>A>	+		40MG	N200603	001	Oct 28, 2010	Apr	CRLD	
>A>			80MG	N200603	002	Oct 28, 2010	Apr	CRLD	
>A>			120MG	N200603	004	Apr 26, 2012	Apr	NEWA	

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE IN PLASTIC CONTAINER

	HOSPIRA	20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Jan	NEWA
		40GM/1000ML(40MG/ML)	N020309	005	Jan 18, 1995	Jan	NEWA

MALATHION

LOTION; TOPICAL
MALATHION

AT	MYLAN PHARMS INC	0.5%	A078743	001	Mar 06, 2009	Feb	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	12.5MG	A200294	001	Apr 13, 2012	Mar	NEWA
AA		25MG	A200294	002	Apr 13, 2012	Mar	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
MEDROXYPROGESTERONE ACETATE

>D> AB	TEVA PARENTERAL	150MG/ML	A076552	001	Oct 27, 2004	Apr	DISC
>A>	@	150MG/ML	A076552	001	Oct 27, 2004	Apr	DISC

MEMANTINE HYDROCHLORIDE

TABLET; ORAL
MEMANTINE HYDROCHLORIDE

	@ ORCHID HLTHCARE	5MG	A090044	001	Mar 12, 2012	Mar	DISC
AB		5MG	A090044	001	Mar 12, 2012	Feb	NEWA
	@	10MG	A090044	002	Mar 12, 2012	Mar	DISC
AB		10MG	A090044	002	Mar 12, 2012	Feb	NEWA

NAMENDA

	FOREST LABS	5MG	N021487	001	Oct 16, 2003	Mar	CTEC
AB		5MG	N021487	001	Oct 16, 2003	Feb	CTEC
+		10MG	N021487	002	Oct 16, 2003	Mar	CTEC
AB +		10MG	N021487	002	Oct 16, 2003	Feb	CTEC

MESALAMINE

SUPPOSITORY; RECTAL
ROWASA

	@ MEDA PHARMS	500MG	N019919	001	Dec 18, 1990	Jan	CAHN

MESNA

INJECTABLE; INTRAVENOUS
MESNA

AP	MYLAN INSTITUTIONAL	100MG/ML	A076488	001	Mar 08, 2012	Feb	NEWA

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

AB	MARKSANS PHARMA	500MG	A090888	001	Mar 12, 2012	Feb	NEWA
AB		850MG	A090888	002	Mar 12, 2012	Feb	NEWA
AB		1GM	A090888	003	Mar 12, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

AB1	INVENTIA HLTHCARE	500MG	A201991	001	Jan 18, 2012	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

>D>	AB	RANBAXY	750MG	A077211	001	Jun 29, 2005	Apr	DISC
>D>	AB1	RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004	Apr	DISC
>A>	@		500MG	A076413	001	Jun 18, 2004	Apr	DISC
>A>	@		750MG	A077211	001	Jun 29, 2005	Apr	DISC

>D> METFORMIN HYDROCHLORIDE; SAXAGLIPTIN

>D> TABLET, EXTENDED RELEASE; ORAL
>D> KOMBIGLYZE XR

>D>		BRISTOL MYERS SQUIBB	500MG;5MG	N200678	001	Nov 05, 2010	Apr	CAIN
>D>			1GM;2.5MG	N200678	003	Nov 05, 2010	Apr	CAIN
>D>	+		1GM;5MG	N200678	002	Nov 05, 2010	Apr	CAIN

>A> METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

>A> TABLET, EXTENDED RELEASE; ORAL
>A> KOMBIGLYZE XR

>A>		BRISTOL MYERS SQUIBB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Apr	CAIN
>A>			1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Apr	CAIN
>A>	+		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Apr	CAIN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL
JANUMET XR

		MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Feb	NEWA
			1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Feb	NEWA
	+		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Feb	NEWA

METHIMAZOLE

TABLET; ORAL
METHIMAZOLE

AB		BOCA PHARMA	5MG	A202068	001	Mar 07, 2012	Feb	NEWA
AB			10MG	A202068	002	Mar 07, 2012	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

AA		SOLCO HLTHCARE	500MG	A086989	001		Mar	CMFD
AA			750MG	A086988	001		Mar	CMFD

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE PRESERVATIVE FREE

AP		APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266	001	Feb 26, 1999	Jan	CMFD
AP		PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171	001	Feb 27, 2012	Feb	NEWA

METHOTREXATE SODIUM

AP	+	BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Feb	CTEC

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+	MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767	001	Apr 30, 2007	Feb	CAHN
AP		ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar	NEWA
AP			EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar	NEWA
AP			EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar	NEWA

		INJECTABLE; INJECTION							
		METHOTREXATE SODIUM PRESERVATIVE FREE							
AP		ONCO THERAPIES LTD	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Mar	NEWA	
AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	Mar	NEWA	
		METHYCLOTHIAZIDE							
		TABLET; ORAL							
		ENDURON							
		@ ABBOTT LABS PHARM	2.5MG	N012524	001		Mar	DISC	
		@	5MG	N012524	004		Mar	DISC	
		METHYCLOTHIAZIDE							
AB	+	MYLAN PHARMS INC	5MG	A087672	001	Aug 17, 1982	Mar	CRLD	
		METHYLDOPATE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		METHYLDOPATE HYDROCHLORIDE							
		@ TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991	Mar	DISC	
		METHYLPHENIDATE HYDROCHLORIDE							
		TABLET; ORAL							
		METHYLPHENIDATE HYDROCHLORIDE							
AB		SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012	Feb	NEWA	
AB			10MG	A090710	002	Mar 15, 2012	Feb	NEWA	
AB			20MG	A090710	003	Mar 15, 2012	Feb	NEWA	
		METHYLPREDNISOLONE SODIUM SUCCINATE							
		INJECTABLE; INJECTION							
		METHYLPREDNISOLONE SODIUM SUCCINATE							
		@ TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992	Mar	DISC	
		METOCLOPRAMIDE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		METOCLOPRAMIDE HYDROCHLORIDE							
		@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Jan	DISC	
		METRONIDAZOLE							
		CREAM; TOPICAL							
		METRONIDAZOLE							
AB		FOUGERA PHARMS	0.75%	A076408	001	May 28, 2004	Jan	CAHN	
		NORITATE							
>D>	+	SANOFI AVENTIS US	1%	N020743	001	Sep 26, 1997	Apr	CAHN	
>A>	+	VALEANT INTL	1%	N020743	001	Sep 26, 1997	Apr	CAHN	
		GEL; TOPICAL							
		METRONIDAZOLE							
AB		FOUGERA PHARMS	0.75%	A077018	001	Jun 06, 2006	Jan	CAHN	
		LOTION; TOPICAL							
		METRONIDAZOLE							
AB		FOUGERA PHARMS	0.75%	A077197	001	May 24, 2006	Jan	CAHN	
		MIDAZOLAM HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		MIDAZOLAM HYDROCHLORIDE							
AP		GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696	001	Feb 29, 2012	Feb	NEWA	
AP			EQ 5MG BASE/ML	A090850	001	Jan 25, 2012	Jan	NEWA	

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
PROAMATINE

AB		SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996	Jan	CAHN
AB	+		5MG	N019815	002	Sep 06, 1996	Jan	CAHN
AB			10MG	N019815	003	Mar 20, 2002	Jan	CAHN

MIFEPRISTONE

TABLET; ORAL
KORLYM

	+	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012	Feb	NEWA

MITOMYCIN

FOR SOLUTION; TOPICAL
MITOSOL

	+	MOBIUS THERAP	0.2MG/VIAL	N022572	001	Feb 07, 2012	Feb	NEWA

MOMETASONE FUROATE

CREAM; TOPICAL
MOMETASONE FUROATE

AB		FOUGERA PHARMS	0.1%	A076171	001	Apr 08, 2005	Jan	CAHN

LOTION; TOPICAL
MOMETASONE FUROATE

AB		FOUGERA PHARMS	0.1%	A075919	001	Nov 29, 2007	Jan	CAHN

OINTMENT; TOPICAL
MOMETASONE FUROATE

AB		FOUGERA PHARMS	0.1%	A077061	001	Mar 28, 2005	Jan	CAHN

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

>A>	AB	RANBAXY LABS LTD	15MG	A078761	001	May 11, 2012	Apr	NEWA
>A>	AB		30MG	A078761	002	May 11, 2012	Apr	NEWA
>A>	AB		60MG	A078761	003	May 11, 2012	Apr	NEWA
>A>	AB		100MG	A078761	004	May 11, 2012	Apr	NEWA
>A>	AB		200MG	A078761	005	May 11, 2012	Apr	NEWA

MUPIROCIN

OINTMENT; TOPICAL
MUPIROCIN

AB		FOUGERA PHARMS	2%	A065192	001	Nov 30, 2005	Jan	CAHN

NABUMETONE

TABLET; ORAL
NABUMETONE

AB		PROSAM LABS	500MG	A079093	001	Feb 27, 2009	Feb	CMFD
AB			750MG	A079093	002	Feb 27, 2009	Feb	CMFD

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIN

	+	MERZ PHARMS	2%	N019599	002	Jan 13, 2012	Jan	NEWA

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HYDROCHLORIDE

	AB		SUN PHARMA GLOBAL	50MG	A090356	001	Feb 24, 2012	Feb	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
NARATRIPTAN

>A>	AB		ORCHID HLTHCARE	EQ 1MG BASE	A091441	001	Apr 30, 2012	Apr	NEWA
>A>	AB			EQ 2.5MG BASE	A091441	002	Apr 30, 2012	Apr	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>D>	AB		RANBAXY	75MG;25MG	A076951	001	Mar 30, 2005	Apr	DISC
>A>		@	RANBAXY LABS LTD	75MG;25MG	A076951	001	Mar 30, 2005	Apr	DISC

NITROGLYCERIN

OINTMENT; INTRA-ANAL
RECTIV

		+	APTALIS PHARMA	0.4%	N021359	001	Jun 21, 2011	Jan	CAHN

NIZATIDINE

CAPSULE; ORAL
AXID

		@	SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988	Mar	DISC
		@		300MG	N019508	002	Apr 12, 1988	Mar	DISC

NIZATIDINE

>D>	AB		MYLAN	150MG	A075934	001	Jul 09, 2002	Apr	DISC
>D>	AB			300MG	A075806	002	Jul 05, 2002	Apr	CRLD
>D>	AB			300MG	A075934	002	Jul 09, 2002	Apr	DISC
>A>		@	MYLAN PHARMS INC	150MG	A075934	001	Jul 09, 2002	Apr	DISC
>A>		@		300MG	A075934	002	Jul 09, 2002	Apr	DISC
>A>	AB	+		300MG	A075806	002	Jul 05, 2002	Apr	CRLD

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
NOREPINEPHRINE BITARTRATE

	AP		SINTETICA	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Mar	NEWA

NYSTATIN

CREAM; TOPICAL
NYSTATIN

	AT		FOUGERA PHARMS	100,000 UNITS/GM	A062129	001		Jan	CAHN

OINTMENT; TOPICAL
NYSTATIN

	AT	+	FOUGERA PHARMS	100,000 UNITS/GM	A062124	002	Sep 23, 1982	Jan	CAHN

OFLOXACIN

TABLET; ORAL
OFLOXACIN

>D>	AB		RANBAXY	200MG	A076220	001	Sep 02, 2003	Apr	DISC
>D>	AB			300MG	A076220	002	Sep 02, 2003	Apr	DISC
>D>	AB			400MG	A076220	003	Sep 02, 2003	Apr	DISC
>A>		@	RANBAXY LABS LTD	200MG	A076220	001	Sep 02, 2003	Apr	DISC

TABLET; ORAL
OFLOXACIN

>A>		@ RANBAXY LABS LTD	300MG	A076220	002	Sep 02, 2003	Apr	DISC
>A>		@	400MG	A076220	003	Sep 02, 2003	Apr	DISC

OLANZAPINE

INJECTABLE; INTRAMUSCULAR
OLANZAPINE

	AP	PHARMAFORCE	10MG/VIAL	A201741	001	Mar 20, 2012	Mar	NEWA
	AP	SANDOZ INC	10MG/VIAL	A201588	001	Oct 24, 2011	Mar	CAHN

TABLET; ORAL
OLANZAPINE

>A>	AB	APOTEX INC	2.5MG	A090798	001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A090798	002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A090798	003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A090798	004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A090798	005	Apr 23, 2012	Apr	NEWA
>A>	AB		20MG	A090798	006	Apr 23, 2012	Apr	NEWA
>A>	AB	AUROBINDO PHARMA LTD	2.5MG	A202050	001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A202050	002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A202050	003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A202050	004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A202050	005	Apr 23, 2012	Apr	NEWA
>A>	AB		20MG	A202050	006	Apr 23, 2012	Apr	NEWA
>A>	AB	DR REDDYS LABS LTD	2.5MG	A076255	001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A076255	002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A076255	003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A076255	004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A076133	001	Apr 23, 2012	Apr	NEWA
>A>	AB	MYLAN	2.5MG	A076866	001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A076866	002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A076866	003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A076866	004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A076866	005	Apr 23, 2012	Apr	NEWA
>A>	AB		20MG	A076866	006	Apr 23, 2012	Apr	NEWA
>A>	AB	ORCHID HLTHCARE	2.5MG	A202287	001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A202287	002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A202287	003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A202287	004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A202287	005	Apr 23, 2012	Apr	NEWA
>A>	AB		20MG	A202287	006	Apr 23, 2012	Apr	NEWA
>A>	AB	SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A091038	002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A091038	003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A091038	004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A091038	005	Apr 23, 2012	Apr	NEWA
>A>	AB		20MG	A091038	006	Apr 23, 2012	Apr	NEWA
>A>	AB	TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A091434	002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A091434	003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A091434	004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A091434	005	Apr 23, 2012	Apr	NEWA
>A>	AB		20MG	A091434	006	Apr 23, 2012	Apr	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE

	AB	BARR LABS INC	5MG	A077243	001	Jan 30, 2012	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE

AB		BARR LABS INC	10MG	A077243	002	Jan 30, 2012	Jan	NEWA
AB			15MG	A077243	003	Jan 30, 2012	Jan	NEWA
AB			20MG	A077243	004	Jan 30, 2012	Jan	NEWA
AB		SUN PHARM INDS	5MG	A090881	001	Feb 28, 2012	Feb	NEWA
AB			10MG	A090881	002	Feb 28, 2012	Feb	NEWA
AB			15MG	A090881	003	Feb 28, 2012	Feb	NEWA
AB			20MG	A090881	004	Feb 28, 2012	Feb	NEWA

OMEPRAZOLE

******; ORAL
OMEPRAZOLE

>A>	AB	DR REDDYS LABS LTD	10MG	A078490	002	Mar 16, 2009	Apr	NEWA
>A>	AB		20MG	A078490	003	Mar 16, 2009	Apr	NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL
TAMIFLU

	+	ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Jan	CRLD

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

AP		SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012	Mar	NEWA
AP			EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012	Mar	NEWA
AP			EQ 10GM BASE/VIAL	A091245	001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)
OXALIPLATIN

AP	+	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Mar	CRLD
AP	+		100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Mar	CRLD

OXICONAZOLE NITRATE

CREAM; TOPICAL
OXISTAT

	+	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Jan	CAHN

OXYBUTYNIN

GEL, METERED; TRANSDERMAL
ANTUROL

>A>	+	ARROW INTL	3%	N202513	001	Dec 07, 2011	Apr	CAHN
>D>	+	WATSON LABS INC	3%	N202513	001	Dec 07, 2011	Apr	CAHN
	+		3%	N202513	001	Dec 07, 2011	Feb	CAHN

OXYBUTYNIN CHLORIDE

TABLET; ORAL
DITROPAN

	@	JANSSEN PHARMS	5MG	N017577	001		Mar	DISC

OXYBUTYNIN CHLORIDE

AB	+	VINTAGE PHARMS	5MG	A075079	001	Oct 31, 1997	Mar	CRLD

TABLET, EXTENDED RELEASE; ORAL
OXYBUTYNIN CHLORIDE

AB		MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Mar	NEWA

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

+		VISTAPHARM	5MG/5ML	N201194	001	Jan 12, 2012	Jan	NEWA

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

>A>	AB		MALLINCKRODT INC	5MG	A076758	003	Mar 19, 2007	Apr	NEWA

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

		@	TEVA PARENTERAL	10USP UNITS/ML (10USP UNITS/ML)	A077453	001	Jan 24, 2008	Jan	DISC
		@		100USP UNITS/10ML (10USP UNITS/ML)	A077453	002	Jan 24, 2008	Mar	DISC

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

		@	CORDEN PHARMA	6MG/ML	N020262	001	Dec 29, 1992	Mar	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

		@	NOVARTIS	30MG/VIAL	N020036	001	Oct 31, 1991	Mar	DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

			ABBOTT LABS	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725	001	Apr 30, 2009	Feb	CAHN
				60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725	002	Apr 30, 2009	Feb	CAHN
	+			120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725	003	Apr 30, 2009	Feb	CAHN

ULTRESA

			APTALIS PHARMA US	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012	Mar	NEWA
				41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012	Mar	NEWA
	+			46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012	Mar	NEWA

ZENPEP

>A>			APTALIS PHARMA US	16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210	005	Jun 15, 2011	Apr	NEWA
>D>		+		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009	Apr	CRLD
>A>				109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009	Apr	CRLD
>A>		+		136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210	006	Jul 13, 2011	Apr	NEWA

TABLET; ORAL

VIOKACE

			APTALIS PHARMA US	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Mar	NEWA
	+			78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Mar	NEWA

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

>A>	AB	APOTEX INC	EQ 20MG BASE	A090807	001	May 02, 2012	Apr	NEWA
>A>	AB		EQ 40MG BASE	A090807	002	May 02, 2012	Apr	NEWA
	AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A200821	001	Feb 16, 2012	Jan	NEWA
	AB		EQ 40MG BASE	A200821	002	Feb 16, 2012	Jan	NEWA
>A>	AB	RANBAXY LABS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr	NEWA
>A>	AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr	NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968	001	Jun 21, 2010	Feb	CMFD
AB		EQ 20MG BASE	A076968	002	Jun 21, 2010	Feb	CMFD
AB		EQ 30MG BASE	A076968	003	Jun 21, 2010	Feb	CMFD
AB		EQ 40MG BASE	A076968	004	Jun 21, 2010	Feb	CMFD

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	Mar	NEWA
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	Mar	NEWA

OMONTYS PRESERVATIVE FREE

+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	Mar	NEWA
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	Mar	NEWA
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012	Mar	NEWA
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012	Mar	NEWA
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012	Mar	NEWA
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012	Mar	NEWA

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246	001		Feb	CAHN

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB	XOMA	2MG	N020184	001	Dec 30, 1993	Jan	CAHN
AB		4MG	N020184	002	Dec 30, 1993	Jan	CAHN
AB	+	8MG	N020184	003	Dec 30, 1993	Jan	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	LANNETT	15MG	A087022	002	Jan 20, 2012	Feb	NEWA

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

	@ SANDOZ INC	30MG	A088605	001	Sep 28, 1987	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL
SUPRENZA

>D>		+	CITIUS PHARMS	30MG	N202088	002	Jun 13, 2011	Apr	CRLD
>A>				30MG	N202088	002	Jun 13, 2011	Apr	CRLD
>D>				37.5MG	N202088	003	Mar 27, 2012	Apr	CRLD
>A>		+		37.5MG	N202088	003	Mar 27, 2012	Apr	CRLD
				37.5MG	N202088	003	Mar 27, 2012	Mar	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
PHENTERMINE RESIN COMPLEX

		+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011	Jan	CRLD
		+		EQ 30MG BASE	A040872	002	Jul 28, 2011	Jan	CRLD

PHYTONADIONE

INJECTABLE; INJECTION
PHYTONADIONE

	BP	+	INTL MEDICATION	1MG/0.5ML	A083722	001		Feb	CRLD

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
ACTOS

			TAKEDA PHARMS USA	EQ 15MG BASE	N021073	001	Jul 15, 1999	Mar	CAHN
				EQ 30MG BASE	N021073	002	Jul 15, 1999	Mar	CAHN
		+		EQ 45MG BASE	N021073	003	Jul 15, 1999	Mar	CAHN

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
K+10

		@	FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987	Mar	DISC

KAON CL-10

		@	SAVAGE LABS	10MEQ	N017046	002		Mar	DISC

KLOR-CON M20

	AB	+	UPSHER-SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Mar	CRLD

KLOTRIX

		@	APOTHECON	10MEQ	N017850	001		Mar	DISC

POTASSIUM CHLORIDE

		@	NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002	Mar	DISC
		@	SCHERING	10MEQ	N019439	002	Jun 13, 1986	Mar	DISC
		@		20MEQ	N019439	001	Jun 13, 1986	Mar	DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL
POTASSIUM CITRATE

		@	NOVA K	10MEQ/PACKET	N019647	002	Oct 13, 1988	Feb	CAHN
		@		20MEQ/PACKET	N019647	001	Oct 13, 1988	Feb	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

>A>	AB		APOTEX INC	0.125MG	A090151	001	Apr 30, 2012	Apr	NEWA
>A>	AB			0.25MG	A090151	002	Apr 30, 2012	Apr	NEWA
>A>	AB			0.5MG	A090151	003	Apr 30, 2012	Apr	NEWA
>A>	AB			0.75MG	A090151	006	Apr 30, 2012	Apr	NEWA
>A>	AB			1MG	A090151	004	Apr 30, 2012	Apr	NEWA
>A>	AB			1.5MG	A090151	005	Apr 30, 2012	Apr	NEWA

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVASTATIN SODIUM

>D>	AB	RANBAXY	10MG	A076445	001	Apr 23, 2007	Apr	DISC
>D>	AB		20MG	A076445	002	Apr 23, 2007	Apr	DISC
>D>	AB		40MG	A076445	003	Apr 23, 2007	Apr	DISC
>D>	AB		80MG	A076445	004	Apr 23, 2007	Apr	DISC
>A>		@ RANBAXY LABS LTD	10MG	A076445	001	Apr 23, 2007	Apr	DISC
>A>		@	20MG	A076445	002	Apr 23, 2007	Apr	DISC
>A>		@	40MG	A076445	003	Apr 23, 2007	Apr	DISC
>A>		@	80MG	A076445	004	Apr 23, 2007	Apr	DISC

PREDNICARBATE

CREAM; TOPICAL
PREDNICARBATE

	AB	FOUGERA PHARMS	0.1%	A077287	001	Sep 19, 2006	Jan	CAHN

OINTMENT; TOPICAL
PREDNICARBATE

	AB	FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007	Jan	CAHN

PREGABALIN

CAPSULE; ORAL
LYRICA

		PF PRISM	25MG	N021446	001	Dec 30, 2004	Jan	CAHN
			50MG	N021446	002	Dec 30, 2004	Jan	CAHN
			75MG	N021446	003	Dec 30, 2004	Jan	CAHN
			100MG	N021446	004	Dec 30, 2004	Jan	CAHN
			150MG	N021446	005	Dec 30, 2004	Jan	CAHN
			200MG	N021446	006	Dec 30, 2004	Jan	CAHN
			225MG	N021446	007	Dec 30, 2004	Jan	CAHN
	+		300MG	N021446	008	Dec 30, 2004	Jan	CAHN

SOLUTION; ORAL
LYRICA

	+	PF PRISM	20MG/ML	N022488	001	Jan 04, 2010	Jan	CAHN

PROGESTERONE

CAPSULE; ORAL
PROGESTERONE

	AB	TEVA PHARMS	100MG	A202121	001	Feb 29, 2012	Feb	NEWA
	AB		200MG	A202121	002	Feb 29, 2012	Feb	NEWA

PROMETRIUM

	AB	ABBOTT LABS	100MG	N019781	001	May 14, 1998	Feb	CFTG
	AB	+	200MG	N019781	002	Oct 15, 1999	Feb	CFTG

QUETIAPINE FUMARATE

TABLET; ORAL
QUETIAPINE FUMARATE

	AB	ACCORD HLTHCARE INC	EQ 25MG BASE	A202152	001	Mar 27, 2012	Mar	NEWA
	AB		EQ 50MG BASE	A202152	002	Mar 27, 2012	Mar	NEWA
	AB		EQ 100MG BASE	A202152	003	Mar 27, 2012	Mar	NEWA
	AB		EQ 200MG BASE	A202152	004	Mar 27, 2012	Mar	NEWA
	AB		EQ 300MG BASE	A202152	005	Mar 27, 2012	Mar	NEWA
	AB		EQ 400MG BASE	A202152	006	Mar 27, 2012	Mar	NEWA
	AB	APOTEX INC	EQ 25MG BASE	A090960	001	Mar 27, 2012	Mar	NEWA
	AB		EQ 50MG BASE	A090960	002	Mar 27, 2012	Mar	NEWA

TABLET; ORAL

QUETIAPINE FUMARATE

AB		APOTEX INC	EQ 100MG BASE	A090960	003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A090960	004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A090960	005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A090960	006	Mar 27, 2012	Mar	NEWA
AB		AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A091388	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A091388	003	Mar 27, 2012	Mar	NEWA
AB			EQ 150MG BASE	A091388	004	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A091388	005	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A091388	006	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A091388	007	Mar 27, 2012	Mar	NEWA
AB		DR REDDYS LABS LTD	EQ 25MG BASE	A077380	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A077380	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A077380	003	Mar 27, 2012	Mar	NEWA
AB			EQ 150MG BASE	A077380	004	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A077380	005	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A077380	006	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A077380	007	Mar 27, 2012	Mar	NEWA
AB		LUPIN LTD	EQ 25MG BASE	A201109	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A201109	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A201109	003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A201109	004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A201109	005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A201109	006	Mar 27, 2012	Mar	NEWA
AB		MYLAN PHARMS INC	EQ 25MG BASE	A090323	001	Mar 27, 2012	Mar	NEWA
AB		ROXANE	EQ 25MG BASE	A090120	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A090749	001	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A090749	002	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A090749	003	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A090749	004	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A090749	005	Mar 27, 2012	Mar	NEWA
AB		SUN PHARMA GLOBAL	EQ 25MG BASE	A201190	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A201190	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A201190	003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A201190	004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A201190	005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A201190	006	Mar 27, 2012	Mar	NEWA
AB		TEVA PHARMS	EQ 25MG BASE	A077745	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A077745	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A077745	003	Mar 27, 2012	Mar	NEWA
AB			EQ 150MG BASE	A077745	004	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A077745	005	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A077745	006	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A077745	007	Mar 27, 2012	Mar	NEWA
AB		TORRENT PHARMS LTD	EQ 25MG BASE	A200363	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A200363	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A200363	003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A200363	004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A200363	005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A200363	006	Mar 27, 2012	Mar	NEWA

SEROQUEL

AB	+	ASTRAZENECA	EQ 25MG BASE	N020639	001	Sep 26, 1997	Mar	CFTG
AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	Mar	CFTG
AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	Mar	CFTG

TABLET; ORAL
SEROQUEL

AB		ASTRAZENECA	EQ 200MG BASE	N020639	003	Sep 26, 1997	Mar	CFTG
AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	Mar	CFTG
AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	Mar	CFTG

RAMIPRIL

CAPSULE; ORAL
RAMIPRIL

>D>	AB	RANBAXY	5MG	A078849	001	Mar 06, 2009	Apr	DISC
>D>	AB		10MG	A078849	002	Mar 06, 2009	Apr	DISC
>A>		@ RANBAXY LABS LTD	5MG	A078849	001	Mar 06, 2009	Apr	DISC
>A>		@	10MG	A078849	002	Mar 06, 2009	Apr	DISC

TABLET; ORAL
ALTACE

		@ KING PFIZER	1.25MG	N022021	001	Feb 27, 2007	Jan	DISC
		@	2.5MG	N022021	002	Feb 27, 2007	Jan	DISC
		@	5MG	N022021	003	Feb 27, 2007	Jan	DISC
		@	10MG	N022021	004	Feb 27, 2007	Jan	DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
ZANTAC

AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Mar	CAHN

ZANTAC IN PLASTIC CONTAINER

	+	COVIS PHARMA	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Mar	CAHN
	@		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Mar	CAHN

RIFAMPIN

CAPSULE; ORAL
RIMACTANE

AB		PROSAM LABS	300MG	N050429	001		Feb	CMFD

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL
EDURANT

	+	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011	Feb	CAHN

RISPERIDONE

TABLET; ORAL
RISPERIDONE

AB		PROSAM LABS	0.25MG	A078071	001	Jun 17, 2009	Feb	CMFD
AB			0.5MG	A078071	002	Jun 17, 2009	Feb	CMFD
AB			1MG	A078071	003	Jun 17, 2009	Feb	CMFD
AB			2MG	A078071	004	Jun 17, 2009	Feb	CMFD
AB			3MG	A078071	005	Jun 17, 2009	Feb	CMFD
AB			4MG	A078071	006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERIDONE

AB		TEVA	0.5MG	A076908	001	Mar 12, 2012	Feb	NEWA
AB			1MG	A076908	002	Mar 12, 2012	Feb	NEWA
AB			2MG	A076908	003	Mar 12, 2012	Feb	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
ROPINIROLE HYDROCHLORIDE

	AB	APOTEX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Jan	NEWA
	AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Jan	NEWA
	AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Jan	NEWA
	AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Jan	NEWA
	AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Jan	NEWA
	AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Jan	NEWA
	AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
REQUIP XL

>D>		+ SMITHKLINE BEECHAM	EQ 2MG BASE	N022008	001	Jun 13, 2008	Apr	CFTG
>A>	AB	+	EQ 2MG BASE	N022008	001	Jun 13, 2008	Apr	CFTG
>D>			EQ 4MG BASE	N022008	003	Jun 13, 2008	Apr	CFTG
>A>	AB		EQ 4MG BASE	N022008	003	Jun 13, 2008	Apr	CFTG
>D>			EQ 6MG BASE	N022008	006	Apr 10, 2009	Apr	CFTG
>A>	AB		EQ 6MG BASE	N022008	006	Apr 10, 2009	Apr	CFTG
>D>			EQ 8MG BASE	N022008	004	Jun 13, 2008	Apr	CFTG
>A>	AB		EQ 8MG BASE	N022008	004	Jun 13, 2008	Apr	CFTG
>D>			EQ 12MG BASE	N022008	005	Oct 31, 2008	Apr	CFTG
>A>	AB		EQ 12MG BASE	N022008	005	Oct 31, 2008	Apr	CFTG
>A>		ROPINIROLE HYDROCHLORIDE						
>A>	AB	ACTAVIS	EQ 2MG BASE	A090869	001	May 17, 2012	Apr	NEWA
>A>	AB		EQ 4MG BASE	A090869	002	May 17, 2012	Apr	NEWA
>A>	AB		EQ 6MG BASE	A090869	003	May 17, 2012	Apr	NEWA
>A>	AB		EQ 8MG BASE	A090869	004	May 17, 2012	Apr	NEWA
>A>	AB		EQ 12MG BASE	A090869	005	May 17, 2012	Apr	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NEUPRO

>A>		UCB INC	1MG/24HR	N021829	004	Apr 02, 2012	Apr	NEWA
>D>		@	2MG/24HR	N021829	001	May 09, 2007	Apr	CMFD
>A>			2MG/24HR	N021829	001	May 09, 2007	Apr	CMFD
>A>			3MG/24HR	N021829	005	Apr 02, 2012	Apr	NEWA
>D>		@	4MG/24HR	N021829	002	May 09, 2007	Apr	CMFD
>A>			4MG/24HR	N021829	002	May 09, 2007	Apr	CMFD
>D>		@	6MG/24HR	N021829	003	May 09, 2007	Apr	CMFD
>A>			6MG/24HR	N021829	003	May 09, 2007	Apr	CMFD
>A>		+	8MG/24HR	N021829	006	Apr 02, 2012	Apr	NEWA

SERTACONAZOLE NITRATE

CREAM; TOPICAL
ERTACZO

		+ VALEANT INTL	2%	N021385	001	Dec 10, 2003	Jan	CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

	AB	PROSAM LABS	EQ 25MG BASE	A078175	001	Jul 21, 2010	Feb	CMFD
	AB		EQ 50MG BASE	A078175	002	Jul 21, 2010	Feb	CMFD
	AB		EQ 100MG BASE	A078175	003	Jul 21, 2010	Feb	CMFD

SIMVASTATIN

TABLET; ORAL
SIMVASTATIN

AB	PROSAM LABS	5MG	A078735	001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735	002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735	003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735	004	Aug 30, 2010	Feb	CMFD
AB		80MG	A078735	005	Aug 30, 2010	Feb	CMFD

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL
BAROS

@	MALLINCKRODT INC	460MG/GM;420MG/GM	N018509	001	Aug 07, 1985	Jan	CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML	A201850	001	Jan 20, 2012	Jan	NEWA

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	MEDEFIL	9MG/ML	N202832	001	Jan 06, 2012	Jan	NEWA

SODIUM IODIDE I-131

CAPSULE; ORAL
SODIUM IODIDE I-131

	JUBILANT DRAXIMAGE	9-100mCi	N021305	006	May 19, 2005	Feb	CAHN
@		2-200mCi	N021305	004	Nov 18, 2004	Jan	DISC

SOLUTION; ORAL
HICON

@	JUBILANT DRAXIMAGE	1-250mCi/0.25ML	N021305	002	Jan 24, 2003	Feb	DISC
@		1-1000mCi/ML	N021305	005	Apr 04, 2006	Feb	DISC
@		1-500mCi/0.5ML	N021305	003	Jan 24, 2003	Feb	DISC
+		250-1000mCi	N021305	007	Dec 05, 2011	Jan	NEWA

SODIUM NITRITE

SOLUTION; INTRAVENOUS
SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML (30MG/ML)	N203922	001	Feb 14, 2012	Feb	NEWA

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS
SODIUM THIOSULFATE

+	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923	001	Feb 14, 2012	Feb	NEWA

SUCCIMER

CAPSULE; ORAL
CHEMET

+	LUNDBECK LLC	100MG	N019998	002	Jan 30, 1991	Mar	CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL
SULFACETAMIDE SODIUM

AB	FOUGERA PHARMS	10%	A077015	001	Nov 17, 2006	Jan	CAHN

SULFANILAMIDE

CREAM; VAGINAL

AVC

+	JAZZ PHARMS COMMERCL	15%	N006530	003	Jan 27, 1987	Mar	CAHN

SUPPOSITORY; VAGINAL

AVC

@	JAZZ PHARMS COMMERCL	1.05GM	N006530	004	Jan 27, 1987	Mar	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP	INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010	Mar	CAHN

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+	MERCK SHARP DOHME	0.0015%	N202514	001	Feb 10, 2012	Feb	NEWA

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577	001	Jan 18, 2012	Jan	NEWA

TABLET; ORAL

VIREAD

>A>	GILEAD SCIENCES INC	150MG	N021356	002	Jan 18, 2012	Apr	NEWA
>A>		200MG	N021356	003	Jan 18, 2012	Apr	NEWA
>A>		250MG	N021356	004	Jan 18, 2012	Apr	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

>D>	AB	RANBAXY	EQ 1MG BASE	A076021	001	Aug 22, 2002	Apr	DISC
>D>	AB		EQ 2MG BASE	A076021	002	Aug 22, 2002	Apr	DISC
>D>	AB		EQ 5MG BASE	A076021	003	Aug 22, 2002	Apr	DISC
>D>	AB		EQ 10MG BASE	A076021	004	Aug 22, 2002	Apr	DISC
>A>		@ RANBAXY LABS LTD	EQ 1MG BASE	A076021	001	Aug 22, 2002	Apr	DISC
>A>		@	EQ 2MG BASE	A076021	002	Aug 22, 2002	Apr	DISC
>A>		@	EQ 5MG BASE	A076021	003	Aug 22, 2002	Apr	DISC
>A>		@	EQ 10MG BASE	A076021	004	Aug 22, 2002	Apr	DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@	TEVA PARENTERAL	1MG/ML	A076853	001	Jul 20, 2004	Jan	DISC

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	0.4%	A076712	001	Feb 18, 2005	Jan	CAHN

SUPPOSITORY; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	80MG	A076850	001	Jul 12, 2006	Jan	CAHN

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

BX	+	ABBOTT LABS	1% (50MG/5GM PACKET)	N021015	002	Feb 28, 2000	Feb	CPOT
			1% (25MG/2.5GM PACKET)	N021015	001	Feb 28, 2000	Feb	CPOT

TESTIM

BX	+	AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454	001	Oct 31, 2002	Feb	CPOT

TESTOSTERONE

		TEVA PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Feb	NEWA
			50MG/5GM PACKET	N202763	002	Feb 14, 2012	Feb	NEWA

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

>A>	AO	HIKMA FARMACEUTICA	200MG/ML	A091244	001	May 01, 2012	Apr	NEWA
	AO	MYLAN INSTITUTIONAL	200MG/ML	A040652	001	Dec 11, 2006	Feb	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

	AO	MYLAN INSTITUTIONAL	200MG/ML	A040647	001	Oct 05, 2009	Feb	CAHN

TETRABENAZINE

TABLET; ORAL

XENAZINE

>D>		VALEANT INTL	12.5MG	N021894	001	Aug 15, 2008	Apr	CAHN
>D>	+		25MG	N021894	002	Aug 15, 2008	Apr	CAHN
>A>		VALEANT PHARMS	12.5MG	N021894	001	Aug 15, 2008	Apr	CAHN
>A>	+		25MG	N021894	002	Aug 15, 2008	Apr	CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

	+	FOUGERA PHARMS	0.05%	A086576	002		Jan	CAHN
			0.1%	A086576	001		Jan	CAHN

SPRAY; NASAL

TYZINE

	+	FOUGERA PHARMS	0.1%	A086576	003		Jan	CAHN

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982	Mar	DISC
	@		40MG/100ML	N018649	001	Jul 26, 1982	Mar	DISC
	@		80MG/100ML	N018649	002	Jul 26, 1982	Mar	DISC
	@		160MG/100ML	N018649	003	Jul 26, 1982	Mar	DISC
	@		200MG/100ML	N018649	004	Jul 26, 1982	Mar	DISC
	@		320MG/100ML	N018649	006	Nov 13, 1985	Mar	DISC
	@		400MG/100ML	N018649	005	Jul 26, 1982	Mar	DISC

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

	@	CEPHALON	6MG	N020646	006	Nov 29, 2005	Jan	DISC
	@		8MG	N020646	007	Nov 29, 2005	Jan	DISC

TABLET; ORAL
GABITRIL
@ CEPHALON 10MG N020646 008 Nov 29, 2005 Jan DISC

TINIDAZOLE

TABLET; ORAL
TINDAMAX
>D> MISSION PHARMA 250MG N021618 001 May 17, 2004 Apr CFTG
>A> AB 250MG N021618 001 May 17, 2004 Apr CFTG
>D> + 500MG N021618 002 May 17, 2004 Apr CFTG
>A> AB + 500MG N021618 002 May 17, 2004 Apr CFTG
>A> TINIDAZOLE
>A> AB NOVEL LABS INC 250MG A202044 001 Apr 30, 2012 Apr NEWA
>A> AB 500MG A202044 002 Apr 30, 2012 Apr NEWA
>A> AB ROXANE 250MG A201172 001 Apr 30, 2012 Apr NEWA
>A> AB 500MG A201172 002 Apr 30, 2012 Apr NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL
TIZANIDINE HYDROCHLORIDE
AB APOTEX INC EQ 2MG BASE A078868 001 Feb 03, 2012 Jan NEWA
AB EQ 4MG BASE A078868 002 Feb 03, 2012 Jan NEWA
AB EQ 6MG BASE A078868 003 Feb 03, 2012 Jan NEWA
ZANAFLEX
AB ACORDA EQ 2MG BASE N021447 001 Aug 29, 2002 Jan CFTG
AB EQ 4MG BASE N021447 002 Aug 29, 2002 Jan CFTG
AB + EQ 6MG BASE N021447 003 Aug 29, 2002 Jan CFTG
TABLET; ORAL
TIZANIDINE HYDROCHLORIDE
AB PROSAM LABS EQ 2MG BASE A076281 001 Oct 20, 2003 Feb CMFD
AB EQ 4MG BASE A076281 002 Oct 20, 2003 Feb CMFD
AB SANDOZ INC EQ 2MG BASE A076280 001 Nov 26, 2002 Feb NEWA

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE
+ MYLAN PHARMS INC 500MG A086445 001 Mar CRLD
@ WATSON LABS 500MG A086109 001 Mar DISC
@ 500MG A087318 001 Mar DISC

TRAMADOL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL
RYBIX ODT
+ SHIONOGI INC 50MG N021693 001 May 05, 2005 Mar CTNA

TRANEXAMIC ACID

INJECTABLE; INJECTION
TRANEXAMIC ACID
AP NEXUS PHARMS 100MG/ML A091596 001 Mar 02, 2012 Feb NEWA

TRANYLCYPROMINE SULFATE

TABLET; ORAL
PARNATE
AB + COVIS PHARMA EQ 10MG BASE N012342 003 Aug 16, 1985 Jan CAHN

TRETINOIN

CREAM; TOPICAL

RENOVA

	+	VALEANT INTL	0.02%	N021108	001	Aug 31, 2000	Jan	CAHN
AB2	+		0.05%	N019963	001	Dec 29, 1995	Jan	CAHN

RETIN-A

AB	+	VALEANT INTL	0.025%	N019049	001	Sep 16, 1988	Jan	CAHN
AB1	+		0.05%	N017522	001		Jan	CAHN
AB	+		0.1%	N017340	001		Jan	CAHN

GEL; TOPICAL

RETIN-A

AB	+	VALEANT INTL	0.01%	N017955	001		Jan	CAHN
AB	+		0.025%	N017579	002		Jan	CAHN

SOLUTION; TOPICAL

RETIN-A

AT	+	VALEANT INTL	0.05%	N016921	001		Jan	CAHN

SWAB; TOPICAL

RETIN-A

	@	VALEANT INTL	0.05%	N016921	002		Jan	CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT		FOUGERA PHARMS	0.025%	A085692	001		Jan	CAHN
AT			0.1%	A085692	003		Jan	CAHN
AT	+		0.5%	A085692	002		Jan	CAHN

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT		FOUGERA PHARMS	0.025%	A040467	001	Apr 21, 2003	Jan	CAHN
AT			0.1%	A040467	002	Apr 21, 2003	Jan	CAHN

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT		FOUGERA PHARMS	0.025%	A085691	001		Jan	CAHN
AT			0.1%	A085691	003		Jan	CAHN
AT			0.5%	A085691	002		Jan	CAHN

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

AB		TEVA PHARMS	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Mar	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		JUBILANT ORGANOSYS	EQ 500MG BASE	A201506	001	Apr 03, 2012	Mar	NEWA
AB			EQ 1GM BASE	A201506	002	Apr 03, 2012	Mar	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

AB		VIROPHARMA	EQ 125MG BASE	N050606	001	Apr 15, 1986	Mar	CFTG
AB	+		EQ 250MG BASE	N050606	002	Apr 15, 1986	Mar	CFTG

VANCOMYCIN HYDROCHLORIDE

AB		AKORN	EQ 125MG BASE	A065478	001	Apr 09, 2012	Mar	NEWA
AB			EQ 250MG BASE	A065478	002	Apr 09, 2012	Mar	NEWA
AB		STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490	001	Apr 09, 2012	Mar	NEWA
AB			EQ 250MG BASE	A065490	002	Apr 09, 2012	Mar	NEWA

CAPSULE; ORAL
VANCOMYCIN HYDROCHLORIDE

AB		WATSON LABS	EQ 125MG BASE	A065510	001	Apr 09, 2012	Mar	NEWA
AB			EQ 250MG BASE	A065510	002	Apr 09, 2012	Mar	NEWA

VANDETANIB

TABLET; ORAL
CAPRELSA

		IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011	Feb	CTNA
	+		300MG	N022405	002	Apr 06, 2011	Feb	CTNA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL
LEVITRA

>D>		BAYER HLTHCARE	2.5MG	N021400	003	Aug 19, 2003	Apr	CFTG
>A>	AB		2.5MG	N021400	003	Aug 19, 2003	Apr	CFTG
>D>			5MG	N021400	001	Aug 19, 2003	Apr	CFTG
>A>	AB		5MG	N021400	001	Aug 19, 2003	Apr	CFTG
>D>			10MG	N021400	002	Aug 19, 2003	Apr	CFTG
>A>	AB		10MG	N021400	002	Aug 19, 2003	Apr	CFTG
>D>		+	20MG	N021400	004	Aug 19, 2003	Apr	CFTG
>A>	AB	+	20MG	N021400	004	Aug 19, 2003	Apr	CFTG
>A>		VARDENAFIL HYDROCHLORIDE						
>A>	AB	TEVA PHARMS	2.5MG	A091347	001	May 03, 2012	Apr	NEWA
>A>	AB		5MG	A091347	002	May 03, 2012	Apr	NEWA
>A>	AB		10MG	A091347	003	May 03, 2012	Apr	NEWA
>A>	AB		20MG	A091347	004	May 03, 2012	Apr	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

AB		ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012	Mar	NEWA
AB			EQ 75MG BASE	A078087	002	Mar 16, 2012	Mar	NEWA
AB			EQ 150MG BASE	A078087	003	Mar 16, 2012	Mar	NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CALAN SR

AB	+	PFIZER	120MG	N019152	003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152	002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152	001	Dec 16, 1986	Feb	CTNA
		VERAPAMIL HYDROCHLORIDE						
>A>	AB	APOTEX CORP	120MG	A200878	001	Apr 20, 2012	Apr	NEWA
>A>	AB		180MG	A200878	002	Apr 20, 2012	Apr	NEWA
>A>	AB		240MG	A200878	003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

FOR SOLUTION; ORAL
SABRIL

>D>	+	LUNDBECK INC	500MG/PACKET	N022006	001	Aug 21, 2009	Apr	CAHN
>A>	+	LUNDBECK LLC	500MG/PACKET	N022006	001	Aug 21, 2009	Apr	CAHN

TABLET; ORAL
SABRIL

>D>	+	LUNDBECK INC	500MG	N020427	001	Aug 21, 2009	Apr	CAHN
>A>	+	LUNDBECK LLC	500MG	N020427	001	Aug 21, 2009	Apr	CAHN

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

>D>			FOREST LABS INC	10MG	N022567	001	Jan 21, 2011	Apr	CRLD
>A>		+		10MG	N022567	001	Jan 21, 2011	Apr	CRLD
>D>		+		40MG	N022567	003	Jan 21, 2011	Apr	CRLD
>A>				40MG	N022567	003	Jan 21, 2011	Apr	CRLD

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

		+	GENENTECH	150MG	N203388	001	Jan 30, 2012	Jan	NEWA

VORICONAZOLE

TABLET; ORAL

VORICONAZOLE

	AB		TEVA PHARMS	50MG	A091658	001	Apr 06, 2012	Mar	NEWA
	AB			200MG	A091658	002	Apr 06, 2012	Mar	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

			@ JAZZ PHARMS COMMERCL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Mar	CAHN

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

		+	JAZZ PHARMS COMMERCL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Mar	CAHN
		+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Mar	CAHN
		+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Mar	CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

>D>	AB		RANBAXY	300MG	A077327	001	Sep 19, 2005	Apr	DISC
>A>			@ RANBAXY LABS LTD	300MG	A077327	001	Sep 19, 2005	Apr	DISC

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

	AB	+	PFIZER	EQ 20MG BASE	N020825	001	Feb 05, 2001	Feb	CFTG
	AB			EQ 40MG BASE	N020825	002	Feb 05, 2001	Feb	CFTG
	AB			EQ 60MG BASE	N020825	003	Feb 05, 2001	Feb	CFTG
	AB			EQ 80MG BASE	N020825	004	Feb 05, 2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

	AB		APOTEX CORP	EQ 20MG BASE	A077561	001	Mar 02, 2012	Feb	NEWA
	AB			EQ 40MG BASE	A077561	002	Mar 02, 2012	Feb	NEWA
	AB			EQ 60MG BASE	A077561	003	Mar 02, 2012	Feb	NEWA
	AB			EQ 80MG BASE	A077561	004	Mar 02, 2012	Feb	NEWA
	AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565	001	Mar 02, 2012	Feb	NEWA
	AB			EQ 40MG BASE	A077565	002	Mar 02, 2012	Feb	NEWA
	AB			EQ 60MG BASE	A077565	003	Mar 02, 2012	Feb	NEWA
	AB			EQ 80MG BASE	A077565	004	Mar 02, 2012	Feb	NEWA
	AB		LUPIN PHARMS	EQ 20MG BASE	A077560	001	Mar 02, 2012	Feb	NEWA
	AB			EQ 40MG BASE	A077560	002	Mar 02, 2012	Feb	NEWA

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

AB	LUPIN PHARMS	EQ 60MG BASE	A077560	003	Mar 02, 2012	Feb	NEWA
AB		EQ 80MG BASE	A077560	004	Mar 02, 2012	Feb	NEWA

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL							
PEPCID COMPLETE							
+ MCNEIL CONS	800MG;10MG;165MG	N020958	001	Oct 16, 2000	Mar	CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL						
CHLORASCRUB MAXI SWABSTICK						
+ PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CAHN
CHLORASCRUB SWAB						
+ PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CAHN
CHLORASCRUB SWABSTICK						
+ PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL						
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE						
STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012	Feb	NEWA

FAMOTIDINE

TABLET, CHEWABLE; ORAL						
PEPCID AC						
@ MCNEIL CONS	10MG	N020801	001	Sep 24, 1998	Mar	CAHN
+	20MG	N020801	002	Dec 17, 2007	Mar	CAHN
TABLET; ORAL						
PEPCID AC						
MCNEIL CONS	10MG	N020325	001	Apr 28, 1995	Mar	CAHN
+	20MG	N020325	002	Sep 23, 2003	Mar	CAHN
PEPCID AC (GELTAB)						
MCNEIL CONS	10MG	N020902	001	Aug 05, 1999	Mar	CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL						
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY						
SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012	Jan	NEWA
WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012	Jan	NEWA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES						
SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012	Jan	NEWA
WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012	Jan	NEWA
FEXOFENADINE HYDROCHLORIDE ALLERGY						
SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012	Jan	NEWA
	180MG	A091567	006	Feb 06, 2012	Jan	NEWA
WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012	Jan	NEWA
	180MG	A079112	006	Feb 08, 2012	Jan	NEWA
FEXOFENADINE HYDROCHLORIDE HIVES						
SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012	Jan	NEWA
	180MG	A091567	005	Feb 06, 2012	Jan	NEWA
WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012	Jan	NEWA
	180MG	A079112	005	Feb 08, 2012	Jan	NEWA

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

	ACCUCAPS INDS	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009	Jan	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

>A>	DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012	Apr	NEWA
>A>	PERRIGO R AND D	15MG	A202319	001	May 18, 2012	Apr	NEWA
>A>	WOCKHARDT LTD	15MG	A202727	001	May 18, 2012	Apr	NEWA

PREVACID 24 HR

>D>	+ NOVARTIS	15MG	N022327	001	May 18, 2009	Apr	CFTG
>A>	+	15MG	N022327	001	May 18, 2009	Apr	CFTG

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTINE

>A>	AVEVA	7MG/24HR	A074612	002	Jul 28, 2003	Apr	NEWA
>A>		14MG/24HR	A074612	003	Oct 20, 1997	Apr	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

	SHASUN CHEMS	EQ 75MG BASE	A201745	001	Feb 29, 2012	Feb	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2012

NO APRIL 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO APRIL 2012 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETYLCYSTEINE - ACETADOTE						
N021539 001	8148356	May 21, 2026	DP			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO						
N022320 001	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
ALBUTEROL SULFATE - PROAIR HFA						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
ALVIMOPAN - ENTEREG						
N021775 001	8112290	Jul 31, 2030	U-1225			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
N022314 001	8101599	May 16, 2023	DP			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
N022314 002	8101599	May 16, 2023	DP			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
N022314 003	8101599	May 16, 2023	DP			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
N022314 004	8101599	May 16, 2023	DP			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
N022314 005	8101599	May 16, 2023	DP			
ARFORMOTEROL TARTRATE - BROVANA						
N021912 001	6589508	Apr 03, 2013	U-793			
	8110706	Nov 09, 2021	DP			
ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE						
A091211 001					PC	Mar 13, 2012
AVANAFIL - STENDRA						
N202276 001					**>A>** NCE	Apr 27, 2017
AVANAFIL - STENDRA						
N202276 002					**>A>** NCE	Apr 27, 2017
AVANAFIL - STENDRA						
N202276 003					**>A>** NCE	Apr 27, 2017
AXITINIB - INLYTA						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
AXITINIB - INLYTA						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N202331 002		5583141	Dec 10, 2013	DS DP U-3			
		5736555	Jun 25, 2012	DS DP U-3			
		7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
BALSALAZIDE DISODIUM - GIAZO							
N022205 001		6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
		7452872	Aug 24, 2026	U-1229			
		7625884	Aug 24, 2026	U-1229			
BECLOMETHASONE DIPROPIONATE - QNASL							
N202813 001		5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
		5683677	Nov 04, 2014	DP			
		5776432	Jul 07, 2015	DP			
		7780038	Jan 24, 2027	DP			
BIMATOPROST - LATISSE							
N022369 001	>A>	8101161	May 25, 2024	U-1218			
	>A>	8101161	May 25, 2024	U-1217			
BIVALIRUDIN - ANGIOMAX							
N020873 001		5196404	Dec 15, 2014	DS DP U-1232			
		5196404	Dec 15, 2014	DS DP U-1040			
		5196404*PED	Jun 15, 2015				
BOCEPREVIR - VICTRELIS							
N202258 001		8119602	Mar 17, 2027	U-1233			
	>A>	RE43298	Feb 22, 2022	DS DP U-1128			
BORTEZOMIB - VELCADE							
N021602 001						NR	Jan 23, 2015
BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN							
N021398 001		8133890	Apr 19, 2022	U-1235			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N021929 001	>A>	8143239	Jan 29, 2023	DP U-1073			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N021929 002	>A>	8143239	Jan 29, 2023	DP U-1073			
BUPIVACAINE - EXPAREL							
N022496 001		6132766	Nov 16, 2013	DP			
BUPIVACAINE - EXPAREL							
N022496 002		6132766	Nov 16, 2013	DP			
CARVEDILOL PHOSPHATE - COREG CR							
N022012 001	>A>	6022562	Oct 17, 2015	DP	Y		
		8101209	Sep 11, 2025	DP			
		8101209*PED	Mar 11, 2026				
CARVEDILOL PHOSPHATE - COREG CR							
N022012 002	>A>	6022562	Oct 17, 2015	DP	Y		
		8101209	Sep 11, 2025	DP			
		8101209*PED	Mar 11, 2026				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARVEDILOL PHOSPHATE - COREG CR							
N022012 003	>A>	6022562	Oct 17, 2015	DP	Y		
		8101209	Sep 11, 2025	DP			
		8101209*PED	Mar 11, 2026				
CARVEDILOL PHOSPHATE - COREG CR							
N022012 004	>A>	6022562	Oct 17, 2015	DP	Y		
		8101209	Sep 11, 2025	DP			
		8101209*PED	Mar 11, 2026				
CICLESONIDE - ZETONNA							
N202129 001		5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
		5605674	Feb 25, 2014	DP			
		5683677	Nov 04, 2014	DP			
		5775321	Jul 07, 2015	DP			
		6006745	Dec 28, 2016	DP			
		6036942	Apr 30, 2013	DP			
		6120752	May 13, 2018	DP			
		6264923	May 13, 2018	DP			
CLEVIDIPINE BUTYRATE - CLEVIPREX							
N022156 001		5856346	Jan 05, 2021	DS DP U-893			
CLEVIDIPINE BUTYRATE - CLEVIPREX							
N022156 002		5856346	Jan 05, 2021	DS DP U-893			
COLCHICINE - COLCRYS							
N022352 001		7964648	Oct 06, 2028	U-1161			
		8097655	Oct 06, 2028	U-1020			
DAPTOMYCIN - CUBICIN							
N021572 002		8129342	Nov 28, 2020	DS DP			
DARUNAVIR ETHANOLATE - PREZISTA							
N021976 001		5843946*PED	Jun 01, 2016				
		6037157	Jun 26, 2016	U-935			
		6037157	Jun 26, 2016	U-1209			
		6037157*PED	Dec 26, 2016				
		6335460	Aug 25, 2012	DS DP U-935			
		6335460	Aug 25, 2012	DS DP U-903			
		6335460	Aug 25, 2012	DS DP U-744			
		6335460	Aug 25, 2012	DS DP U-1209			
		6335460*PED	Feb 25, 2013				
		6703403	Jun 26, 2016	U-935			
		6703403	Jun 26, 2016	U-1209			
		6703403*PED	Dec 26, 2016				
		7470506	Jun 23, 2019	U-935			
		7470506	Jun 23, 2019	U-1209			
		7470506*PED	Dec 23, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 002	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA						
N202895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
DEGARELIX ACETATE - FIRMAGON						
N022201 001	5925730	May 18, 2021	DS DP U-943			
DEGARELIX ACETATE - FIRMAGON						
N022201 002	5925730	May 18, 2021	DS DP U-943			
DEXAMETHASONE - OZURDEX						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
DEXLANSOPRAZOLE - DEXILANT						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
DEXLANSOPRAZOLE - DEXILANT						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
DICLOFENAC POTASSIUM - CAMBIA						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DICLOFENAC POTASSIUM - ZIPSOR							
N022202 001		8110606	Feb 24, 2029	U-980			
DIENOGEST; ESTRADIOL VALERATE - NATAZIA							
N022252 001	**>A>**	8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF							
N202667 001						NP	Feb 01, 2015
DROSPIRENONE; ESTRADIOL - ANGELIQ							
N021355 001						NS	Mar 01, 2015
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA							
N202123 001						**>A>** NCE	May 20, 2016
EPROSARTAN MESYLATE - EPROSARTAN MESYLATE							
A202012 001						PC	Jun 17, 2012
EPROSARTAN MESYLATE - EPROSARTAN MESYLATE							
A202012 002						PC	Jun 17, 2012
ERIBULIN MESYLATE - HALAVEN							
N201532 001		8097648	Jan 22, 2021	U-1096			
ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE							
A076765 001						PC	Sep 10, 2012
ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE							
A076765 002						PC	Sep 10, 2012
ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE							
A076765 003						PC	Sep 10, 2012
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
N021957 001		5877192	May 27, 2014	U-773			
		5877192	May 27, 2014	U-729			
		5877192	May 27, 2014	U-1207			
		5877192*PED	Nov 27, 2014				
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
N021957 002		5877192	May 27, 2014	U-773			
		5877192	May 27, 2014	U-729			
		5877192	May 27, 2014	U-1207			
		5877192*PED	Nov 27, 2014				
ETRAVIRINE - INTELENCE							
N022187 001	**>A>**	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	>A>	6878717	Nov 05, 2019	U-1237			
	>A>	6878717	Nov 05, 2019	U-1016			
	>A>	7037917	Dec 13, 2020	DS DP U-256			
	>A>	7037917	Dec 13, 2020	DS DP U-1237			
	>A>	7037917	Dec 13, 2020	DS DP U-1016			
ETRAVIRINE - INTELENCE							
N022187 002	**>A>**	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	>A>	6878717	Nov 05, 2019	U-1237			
	>A>	6878717	Nov 05, 2019	U-1016			
	>A>	7037917	Dec 13, 2020	DS DP U-256			
	>A>	7037917	Dec 13, 2020	DS DP U-1237			
	>A>	7037917	Dec 13, 2020	DS DP U-1016			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETRAVIRINE - INTELENCE						
N022187 003	**>A>** 6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	>A> 6878717	Nov 05, 2019	U-1237		NCE	Jan 18, 2013
	>A> 6878717	Nov 05, 2019	U-1016			
	>A> 7037917	Dec 13, 2020	DS DP U-1237			
	>A> 7887845	Mar 25, 2019	DP			
	>A> 8003789	Nov 01, 2019	DS DP			
EVEROLIMUS - AFINITOR						
N022334 001					**>A>** I-650	Apr 26, 2015
EVEROLIMUS - AFINITOR						
N022334 002					**>A>** I-650	Apr 26, 2015
EVEROLIMUS - AFINITOR						
N022334 003					**>A>** I-650	Apr 26, 2015
EVEROLIMUS - AFINITOR						
N022334 004	**>A>** 5665772	Sep 09, 2019	DS DP		**>A>** I-650	Apr 26, 2015
	>A> 6004973	Jul 12, 2016	DP		**>A>** I-638	May 05, 2014
	>A> 7297703	Dec 06, 2019	DP		**>A>** I-630	Oct 29, 2013
					>A> NCE	Mar 30, 2014
					>A> ODE	May 05, 2018
					>A> ODE	Oct 29, 2017
EXENATIDE SYNTHETIC - BYDUREON						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
EXENATIDE SYNTHETIC - BYETTA						
N021773 001					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
EXENATIDE SYNTHETIC - BYETTA						
N021773 002					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
EZETIMIBE - ZETIA						
N021445 001					M-109	Jan 24, 2015
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 001					M-109	Jan 24, 2015
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 002					M-109	Jan 24, 2015
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 003					M-109	Jan 24, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 004					M-109	Jan 24, 2015
FAMCICLOVIR - FAMVIR						
N020363 001					M-112	Feb 09, 2015
FAMCICLOVIR - FAMVIR						
N020363 002					M-112	Feb 09, 2015
FAMCICLOVIR - FAMVIR						
N020363 003					M-112	Feb 09, 2015
FENOFIBRATE - FENOGLIDE						
N022118 001	8124125	Oct 01, 2024	DP U-1234			
FENOFIBRATE - FENOGLIDE						
N022118 002	8124125	Oct 01, 2024	DP U-1234			
FENTANYL - SUBSYS						
N202788 001					NP	Jan 04, 2015
FENTANYL - SUBSYS						
N202788 002					NP	Jan 04, 2015
FENTANYL - SUBSYS						
N202788 003					NP	Jan 04, 2015
FENTANYL - SUBSYS						
N202788 004					NP	Jan 04, 2015
FENTANYL - SUBSYS						
N202788 005					NP	Jan 04, 2015
FENTANYL CITRATE - FENTORA						
N021947 001	8092832	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N021947 002	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N021947 003	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N021947 004	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N021947 005	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 001	8088398	Jun 07, 2027	DP U-913			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 002	8088398	Jun 07, 2027	DP U-913			
FINGOLIMOD - GILENYA						
N022527 001 **>A>**	6004565	Sep 23, 2017	U-1086			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLORBETAPIR F-18 - AMYVID						
N202008 001	**>A>** 7687052	Apr 30, 2027	DS DP		**>A>** NCE	Apr 06, 2017
FLORBETAPIR F-18 - AMYVID						
N202008 002	**>A>** 7687052	Apr 30, 2027	DS DP		**>A>** NCE	Apr 06, 2017
FLORBETAPIR F-18 - AMYVID						
N202008 003	**>A>** 7687052	Apr 30, 2027	DS DP		**>A>** NCE	Apr 06, 2017
FLUNISOLIDE - AEROSPAN HFA						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
FOSAMPRENAVIR CALCIUM - LEXIVA						
N021548 001					**>A>** NPP	Apr 27, 2015
					>A> PED	Oct 27, 2015
FOSAMPRENAVIR CALCIUM - LEXIVA						
N022116 001					**>A>** NPP	Apr 27, 2015
					>A> PED	Oct 27, 2015
FOSPROPOFOL DISODIUM - LUSEDRA						
N022244 001	6204257	Jul 01, 2022	DS DP U-945			
GABAPENTIN ENACARBIL - HORIZANT						
N022399 001	8114909	Apr 11, 2026	U-1231			
GABAPENTIN ENACARBIL - HORIZANT						
N022399 002	8114909	Apr 11, 2026	U-1231			
GADOFOSVESET TRISODIUM - ABLAVAR						
N021711 001	6676929	May 04, 2020	DP			
GADOFOSVESET TRISODIUM - ABLAVAR						
N021711 002	6676929	May 04, 2020	DP			
GADOXETATE DISODIUM - EOVIST						
N022090 001	**>A>** 5798092	Apr 25, 2015	DS DP			
	>A> 6039931	Nov 13, 2021	U-1239			
GLYCOPYRROLATE - CUVPOSA						
N022571 001					ODE	Jul 28, 2017
HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE						
A077369 001					**>A>** PC	Sep 26, 2012
HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE						
A077369 002					**>A>** PC	Sep 26, 2012
IMATINIB MESYLATE - GLEEVEC						
N021588 001					ODE	Dec 19, 2015
IMATINIB MESYLATE - GLEEVEC						
N021588 002					ODE	Dec 19, 2015
INGENOL MEBUTATE - PICATO						
N202833 001	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INGENOL MEBUTATE - PICATO						
N202833 002	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
INSULIN DETEMIR RECOMBINANT - LEVEMIR						
N021536 001					>A> M-115	Apr 06, 2015
IOFLUPANE I-123 - DATSCAN						
N022454 001	5310912	Feb 25, 2013	DS			
IRBESARTAN - IRBESARTAN						
A077159 001					>A> PC	Sep 26, 2012
IRBESARTAN - IRBESARTAN						
A077159 002					>A> PC	Sep 26, 2012
IRBESARTAN - IRBESARTAN						
A077159 003					>A> PC	Sep 26, 2012
IVACAFTOR - KALYDECO						
N203188 001	7495103	May 20, 2027	DS DP		NCE	Jan 31, 2017
					ODE	Jan 31, 2019
IVERMECTIN - SKLICE						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
IXABEPILONE - IXEMPRA KIT						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
IXABEPILONE - IXEMPRA KIT						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
KETOCONAZOLE - EXTINA						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE						
A079081 001					PC	May 15, 2012
LENALIDOMIDE - REVLIMID						
N021880 001	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N021880 002	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N021880 003	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N021880 004	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N021880 005	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
LINAGLIPTIN - TRADJENTA						
N201280 001	8119648	Aug 12, 2023	U-774			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
LIRAGLUTIDE RECOMBINANT - VICTOZA						
N022341 001	8114833	Aug 13, 2025	DP		>A> M-115	Apr 06, 2015
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LUBIPROSTONE - AMITIZA						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			
LUBIPROSTONE - AMITIZA						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
LUCINACTANT - SURFAXIN						
N021746 001	**>A>** 5407914	Nov 17, 2012	DS DP U-1242			
LURASIDONE HYDROCHLORIDE - LATUDA						
N200603 001					**>A>** D-134	Apr 26, 2015
LURASIDONE HYDROCHLORIDE - LATUDA						
N200603 002					**>A>** D-134	Apr 26, 2015
LURASIDONE HYDROCHLORIDE - LATUDA						
N200603 003					**>A>** D-134	Apr 26, 2015
					>A> NCE	Oct 28, 2015
LURASIDONE HYDROCHLORIDE - LATUDA						
N200603 004					**>A>** D-134	Apr 26, 2015
					>A> NCE	Oct 28, 2015
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N202270 001	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N202270 002	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N021121 001	**>A>** 8163798	Jul 31, 2017	DP			
	>A> 8163798*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N021121 002	**>A>** 8163798	Jul 31, 2017	DP			
	>A> 8163798*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N021121 003	**>A>** 8163798	Jul 31, 2017	DP			
	>A> 8163798*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N021121 004	**>A>** 8163798	Jul 31, 2017	DP			
	>A> 8163798*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE						
A078458 001					PC	Jul 01, 2012
METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE						
A078458 002					PC	Jul 01, 2012
METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE						
A078458 003					PC	Jul 01, 2012
MICONAZOLE - ORAVIG						
N022404 001	7651698	Sep 11, 2022	U-1051			
MIFEPRISTONE - KORLYM						
N202107 001					NP	Feb 17, 2015
MITOMYCIN - MITOSOL						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
MONTELUKAST SODIUM - SINGULAIR						
N020829 002					NPP	Mar 26, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MONTELUKAST SODIUM - SINGULAIR							
N020830	001					NPP	Mar 26, 2015
MONTELUKAST SODIUM - SINGULAIR							
N020830	002					NPP	Mar 26, 2015
MONTELUKAST SODIUM - SINGULAIR							
N021409	001					NPP	Mar 26, 2015
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N022321	001	**>A>** 8158156	Jun 19, 2027	U-1241			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N022321	002	**>A>** 8158156	Jun 19, 2027	U-1241			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N022321	003	**>A>** 8158156	Jun 19, 2027	U-1241			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N022321	004	**>A>** 8158156	Jun 19, 2027	U-1241			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N022321	005	**>A>** 8158156	Jun 19, 2027	U-1241			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N022321	006	**>A>** 8158156	Jun 19, 2027	U-1241			
NAFTIFINE HYDROCHLORIDE - NAFTIN							
N019599	002					NS	Jan 13, 2015
NICOTINE - NICODERM CQ							
N020165	004	8075911	May 22, 2021	DP			
NICOTINE - NICODERM CQ							
N020165	005	8075911	May 22, 2021	DP			
NICOTINE - NICODERM CQ							
N020165	006	8075911	May 22, 2021	DP			
NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA							
N022068	001	**>A>** 8163904	Aug 23, 2028	DS DP			
NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA							
N022068	002	**>A>** 8163904	Aug 23, 2028	DS DP			
NITRIC OXIDE - INOMAX							
N020845	002	5558083	Nov 22, 2013	DP U-1226			
		5558083*PED	May 22, 2014				
		5732693	Dec 13, 2016	DP U-1230			
		5732693*PED	Jun 13, 2017				
		5752504	Dec 13, 2016	DP U-1230			
		5752504*PED	Jun 13, 2017				
NITRIC OXIDE - INOMAX							
N020845	003	5558083	Nov 22, 2013	DP U-1226			
		5558083*PED	May 22, 2014				
		5732693	Dec 13, 2016	DP U-1230			
		5732693*PED	Jun 13, 2017				
		5752504	Dec 13, 2016	DP U-1230			
		5752504*PED	Jun 13, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NITROGLYCERIN - NITROLINGUAL PUMPSPRAY							
N018705	002	7872049	Mar 14, 2028	DP U-39			
OXCARBAZEPINE - TRILEPTAL							
N021285	001	8119148	Dec 19, 2020	DP U-724			
		8119148*PED	Jun 19, 2021				
OXYBUTYNIN - ANTUROL							
N202513	001	**>A>** 7029694	Apr 26, 2020	DP U-318			
		>A> 7179483	Apr 26, 2020	U-318			
		>A> 7198801	Jun 25, 2022	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N022272	001	8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N022272	002	8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N022272	003	8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N022272	004	8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N022272	005	8114383	Oct 10, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655	001	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655	002	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655	003	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655	004	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655	005	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655	006	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655	007	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
PACLITAXEL - ABRAXANE							
N021660	001	8138229	Dec 09, 2023	DP U-1092			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA						
N022222 001					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA						
N022222 002					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA						
N022222 003					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE						
N022542 001					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE						
N022542 002					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N022210 005					**>A>** NCE	Aug 27, 2014
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N022210 006					**>A>** NCE	Aug 27, 2014
PAZOPANIB HYDROCHLORIDE - VOTRIENT						
N022465 001	8114885	Dec 19, 2021	DS DP		**>A>** I-649	Apr 26, 2015
					>A> ODE	Apr 26, 2019
PAZOPANIB HYDROCHLORIDE - VOTRIENT						
N022465 002	8114885	Dec 19, 2021	DS DP		**>A>** I-649	Apr 26, 2015
					>A> ODE	Apr 26, 2017
PEGINESATIDE ACETATE - OMONTYS						
N202799 007	**>A>** 7084245	May 12, 2024	DS DP U-1238			
	>A> 7414105	May 12, 2024	DS DP U-1238			
	>A> 7528104	May 12, 2024	DS DP			
	>A> 7550433	Jun 02, 2026	U-1238			
	>A> 7919118	May 12, 2024	DS DP			
	>A> 7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS						
N202799 008	**>A>** 7084245	May 12, 2024	DS DP U-1238			
	>A> 7414105	May 12, 2024	DS DP U-1238			
	>A> 7528104	May 12, 2024	DS DP			
	>A> 7550433	Jun 02, 2026	U-1238			
	>A> 7919118	May 12, 2024	DS DP			
	>A> 7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N202799 001	**>A>** 7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	>A> 7414105	May 12, 2024	DS DP U-1238			
	>A> 7528104	May 12, 2024	DS DP			
	>A> 7550433	Jun 02, 2026	U-1238			
	>A> 7919118	May 12, 2024	DS DP			
	>A> 7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N202799 002	**>A>** 7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	>A> 7414105	May 12, 2024	DS DP U-1238			
	>A> 7528104	May 12, 2024	DS DP			
	>A> 7550433	Jun 02, 2026	U-1238			
	>A> 7919118	May 12, 2024	DS DP			
	>A> 7919461	Jun 02, 2026	U-1238			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N202799	003	>A> 7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
		>A> 7414105	May 12, 2024	DS DP U-1238			
		>A> 7528104	May 12, 2024	DS DP			
		>A> 7550433	Jun 02, 2026	U-1238			
		>A> 7919118	May 12, 2024	DS DP			
		>A> 7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N202799	004	>A> 7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
		>A> 7414105	May 12, 2024	DS DP U-1238			
		>A> 7528104	May 12, 2024	DS DP			
		>A> 7550433	Jun 02, 2026	U-1238			
		>A> 7919118	May 12, 2024	DS DP			
		>A> 7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N202799	005	>A> 7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
		>A> 7414105	May 12, 2024	DS DP U-1238			
		>A> 7528104	May 12, 2024	DS DP			
		>A> 7550433	Jun 02, 2026	U-1238			
		>A> 7919118	May 12, 2024	DS DP			
		>A> 7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N202799	006	>A> 7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
		>A> 7414105	May 12, 2024	DS DP U-1238			
		>A> 7528104	May 12, 2024	DS DP			
		>A> 7550433	Jun 02, 2026	U-1238			
		>A> 7919118	May 12, 2024	DS DP			
		>A> 7919461	Jun 02, 2026	U-1238			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N050684	001	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N050684	002	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N050684	003	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N050684	004	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N050750	001	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N050750	002	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N050750	003	8133883	Apr 14, 2023	DP U-282			
PREDNISOLONE ACETATE - FLO-PRED							
N022067	001	>A> 7799331	Oct 11, 2028	DP U-139			
		>A> 7799331	Oct 11, 2028	DP U-1068			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PREDNISOLONE ACETATE - FLO-PRED							
N022067 002	>A>	7799331	Oct 11, 2028	DP U-139			
	>A>	7799331	Oct 11, 2028	DP U-1068			
RALTEGRAVIR POTASSIUM - ISENTRESS							
N022145 001						M-114	Mar 28, 2015
RALTEGRAVIR POTASSIUM - ISENTRESS							
N203045 001		7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
		7217713	Oct 21, 2022	U-257			
		7435734	Oct 21, 2022	U-257			
		7754731	Mar 11, 2029	DS DP U-257			
RALTEGRAVIR POTASSIUM - ISENTRESS							
N203045 002		7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
		7217713	Oct 21, 2022	U-257			
		7435734	Oct 21, 2022	U-257			
		7754731	Mar 11, 2029	DS DP U-257			
REGADENOSON - LEXISCAN							
N022161 001		8106029	Jun 22, 2019	U-1042			
		8106183	Feb 02, 2027	DS			
		8133879	Jun 22, 2019	DP			
RIFAXIMIN - XIFAXAN							
N021361 001	>A>	8158644	Jun 19, 2024	DP			
	>A>	8158781	Jun 19, 2024	DS			
RIFAXIMIN - XIFAXAN							
N022554 001	>A>	8158644	Jun 19, 2024	DP			
	>A>	8158781	Jun 19, 2024	DS			
RILPIVIRINE HYDROCHLORIDE - EDURANT							
N202022 001		8080551	Apr 11, 2023	DS DP			
		8101629	Aug 09, 2022	DP			
ROTIGOTINE - NEUPRO							
N021829 001						I-647	Apr 02, 2015
						I-646	Apr 02, 2015
ROTIGOTINE - NEUPRO							
N021829 002						I-647	Apr 02, 2015
						I-646	Apr 02, 2015
ROTIGOTINE - NEUPRO							
N021829 003						I-647	Apr 02, 2015
						I-646	Apr 02, 2015
ROTIGOTINE - NEUPRO							
N021829 004	>A>	6699498	Nov 27, 2020	DP		>A> I-647	Apr 02, 2015
	>A>	6884434	Mar 30, 2021	DP		>A> I-646	Apr 02, 2015
	>A>	7413747	Mar 18, 2019	DP			
ROTIGOTINE - NEUPRO							
N021829 005	>A>	6699498	Nov 27, 2020	DP		>A> I-647	Apr 02, 2015
	>A>	6884434	Mar 30, 2021	DP		>A> I-646	Apr 02, 2015
	>A>	7413747	Mar 18, 2019	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROTIGOTINE - NEUPRO						
N021829 006	**>A>** 6699498	Nov 27, 2020	DP		**>A>** I-647	Apr 02, 2015
	>A> 6884434	Mar 30, 2021	DP		**>A>** I-646	Apr 02, 2015
	>A> 7413747	Mar 18, 2019	DP			
SILDENAFIL CITRATE - REVATIO						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			PED	Nov 07, 2012
SILDENAFIL CITRATE - REVATIO						
N022473 001	5250534	Mar 27, 2012	DS DP		NDF	Nov 20, 2012
	5250534*PED	Sep 27, 2012			PED	May 20, 2013
SILDENAFIL CITRATE - VIAGRA						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
SILDENAFIL CITRATE - VIAGRA						
N020895 002	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
SILDENAFIL CITRATE - VIAGRA						
N020895 003	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
SODIUM NITRITE - SODIUM NITRITE						
N203922 001					ODE	Jan 14, 2018
SODIUM THIOSULFATE - SODIUM THIOSULFATE						
N203923 001					ODE	Jan 14, 2018
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO						
N022239 001	8118771	Aug 10, 2023	DP			
TAFLUPROST - ZIOPTAN						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 001	8114383	Oct 10, 2024	DP			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 002	8114383	Oct 10, 2024	DP			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 003	8114383	Oct 10, 2024	DP			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 004	8114383	Oct 10, 2024	DP			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 005	8114383	Oct 10, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TELAVANCIN HYDROCHLORIDE - VIBATIV						
N022110 001	8101575	May 01, 2021	DP			
	>A> 8158580	May 01, 2021	DP			
TELAVANCIN HYDROCHLORIDE - VIBATIV						
N022110 002	8101575	May 01, 2021	DP			
	>A> 8158580	May 01, 2021	DP			
TELBIVUDINE - TYZEKA						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			
TEMSIROLIMUS - TORISEL						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		NCE	May 30, 2012
	8026276*PED	Jul 20, 2026			ODE	May 30, 2014
					PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
					PED	Nov 30, 2012
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N021356 001					NPP	Jan 18, 2015
					PED	Jul 18, 2015
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N021356 002	**>A>** 5922695	Jul 25, 2017	DS U-250		**>A>** M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-256		**>A>** NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-999		**>A>** NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-248		**>A>** ODE	Mar 24, 2017
	>A> 5922695*PED	Jan 25, 2018			**>A>** PED	Sep 24, 2017
	>A> 5935946	Jul 25, 2017	DS DP U-999		**>A>** PED	Jul 18, 2015
	>A> 5935946	Jul 25, 2017	DS DP U-248		**>A>** PED	Apr 01, 2014
	>A> 5935946	Jul 25, 2017	DS DP U-250		**>A>** PED	Sep 24, 2013
	>A> 5935946	Jul 25, 2017	DS DP U-256			
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	>A> 6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N021356 003	**>A>** 5922695	Jul 25, 2017	DS U-250		**>A>** M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-256		**>A>** NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-999		**>A>** NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-248		**>A>** ODE	Mar 24, 2017
	>A> 5922695*PED	Jan 25, 2018			**>A>** PED	Sep 24, 2017
	>A> 5935946	Jul 25, 2017	DS DP U-999		**>A>** PED	Jul 18, 2015
	>A> 5935946	Jul 25, 2017	DS DP U-248		**>A>** PED	Apr 01, 2014
	>A> 5935946	Jul 25, 2017	DS DP U-250		**>A>** PED	Sep 24, 2013
	>A> 5935946	Jul 25, 2017	DS DP U-256			
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	>A> 6043230*PED	Jan 25, 2018				
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N021356 004	**>A>** 5922695	Jul 25, 2017	DS U-250		**>A>** M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-256		**>A>** NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-999		**>A>** NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-248		**>A>** ODE	Mar 24, 2017
	>A> 5922695*PED	Jan 25, 2018			**>A>** PED	Sep 24, 2017
	>A> 5935946	Jul 25, 2017	DS DP U-999		**>A>** PED	Jul 18, 2015
	>A> 5935946	Jul 25, 2017	DS DP U-248		**>A>** PED	Apr 01, 2014
	>A> 5935946	Jul 25, 2017	DS DP U-250		**>A>** PED	Sep 24, 2013
	>A> 5935946	Jul 25, 2017	DS DP U-256			
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	>A> 6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N022577 001	5922695	Jul 25, 2017	DS U-250		>A> M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		>A> NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-248		>A> ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			>A> PED	Sep 24, 2017
	5935946	Jul 25, 2017	DP U-999	Y	PED	Jul 18, 2015
	5935946	Jul 25, 2017	DP U-248	Y	>A> PED	Apr 01, 2014
	5935946	Jul 25, 2017	DP U-250	Y	>A> PED	Sep 24, 2013
	5935946	Jul 25, 2017	DP U-256	Y		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
TESTOSTERONE - TESTIM						
N021454 001	>A> 8178518	Apr 21, 2023	DP			
TESTOSTERONE - TESTOSTERONE						
N202763 001					NP	Feb 14, 2015
THALIDOMIDE - THALOMID						
N020785 001	>A> 8143283	Mar 01, 2013	U-1236			
THALIDOMIDE - THALOMID						
N020785 002	>A> 8143283	Mar 01, 2013	U-1236			
THALIDOMIDE - THALOMID						
N020785 003	>A> 8143283	Mar 01, 2013	U-1236			
THALIDOMIDE - THALOMID						
N020785 004	>A> 8143283	Mar 01, 2013	U-1236			
TOPIRAMATE - TOPAMAX						
N020505 001					NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020505 002					NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020505 004					NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020505 005					NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020844 001					NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020844 002					NPP	Jul 15, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPOTECAN HYDROCHLORIDE - HYCAMTIN							
N020981 001	**>A>**	8158645	Dec 10, 2024	DP			
TOPOTECAN HYDROCHLORIDE - HYCAMTIN							
N020981 002	**>A>**	8158645	Dec 10, 2024	DP			
TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE							
A091607 001						PC	Jun 27, 2012
TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE							
A091607 002						PC	Jun 27, 2012
TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE							
A091607 003						PC	Jun 27, 2012
TRAZODONE HYDROCHLORIDE - OLEPTRO							
N022411 001		8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - OLEPTRO							
N022411 002		8133893	Mar 13, 2029	DS DP			
TRIAMCINOLONE ACETONIDE - TRIESENCE							
N022048 001		8128960	Dec 17, 2029	DP			
VEMURAFENIB - ZELBORAF							
N202429 001	**>A>**	8143271	Jun 21, 2026	DS DP			
VISMODEGIB - ERIVEDGE							
N203388 001						NCE	Jan 30, 2017
VORINOSTAT - ZOLINZA							
N021991 001		8093295	May 16, 2026	DP			
		8101663	Mar 04, 2023	U-892			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm